Vtutechnology Press Releases

VALIDOGEN presenting UNLOCK PICHIA insights at PepTalk 2020


VALIDOGEN presenting UNLOCK PICHIA insights at PepTalk 2020


Druck

PRESS RELEASE | VALIDOGEN GmbH

JANUARY 14, 2020

Raaba-Grambach, Austria: Protein expression specialist VALIDOGEN will send two of its leading scientists to San Diego, California, to present insights of its advanced UNLOCK PICHIA protein production toolbox at PepTalk 2020.

Iskandar Dib, VALIDOGEN’s Head of Analytics & DSP and Roland Weis, VALIDOGEN’s Head of Operations, will represent the company at the conference.

Iskandar will deliver a presentation on ‘Boosting VHH Expression Using UNLOCK PICHIA’ on the morning of Day Three of the conference (Wednesday, 22 January, 9.20 am – 9.50 am) as part of the “Effective Expression and Production of Recombinant Proteins” stream.

VHH expression

He will explain how production strains and processes for the manufacture of single-domain antibodies, also known as VHHs, are currently developed at VALIDOGEN´s labs for an increasing number of different applications. Efficient production of VHHs is enabled by VALIDOGEN’s yield-enhancing UNLOCK PICHIA protein production toolbox, comprising a broad diversity of molecular tools and expression strategies.

“We are able to demonstrate significant enhancement of VHH expression applying our technology platform, for example a set of helper factors acting along the way from transcription to secretion,” said Roland Weis.

Productivity through diversity

VALIDOGEN´s UNLOCK PICHIA protein production toolbox including the company´s library of PAOX1 promoter variants provides several advantages. Very high titers along with timely adjusted expression of helper proteins (some available exclusively through VALIDOGEN) as well as lower consumption or complete absence of methanol are features which can significantly contribute to enhanced productivity and product quality and hence substantial reduction in cost of goods for protein manufacturing.

VALIDOGEN´s labs apply their UNLOCK PICHIA tools in a very effective combinatorial fashion simultaneously in pools of expression constructs comprising the gene of interest and potentially also genes encoding for different auxiliary (helper) proteins, thereby generating a broad diversity of genomic arrangements in the host cells resulting in diverse expression profiles and significantly boosted protein production.

In an experimental case study, a set of helper factors acting either in the cytosol or the ER or facilitating translocation of nascent proteins into the ER were co-expressed in order to investigate a potential enhancement of VHH-dimer expression. Results from microscale as well as bioreactor scale showed a 2.0 – 2.7-fold improvement of product yield. Combining all three helper factors in one expression construct led to a 3.5-fold enhancement of product yield as depicted in the graph below.

About VALIDOGEN GmbH

VALIDOGEN GmbH (formerly VTU Technology), a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor-made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

Headquartered in Raaba-Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Holding GmbH.

www.validogen.com and www.unlockpichia.com.

About PepTalk 2020

The Protein Science Week known as PepTalk is one of the largest annual gatherings of protein science researchers in the world. PepTalk features renowned speakers from academia, biotech and pharma who bring global expertise and perspective to the forefront.

The event is organized by CHI – Cambridge HealthTech Institute, with further information at: https://www.chi-peptalk.com.

Media Contacts

Dr. Evelyn Trummer-Gödl, Marketing & Communications, VALIDOGEN GmbH
Email: e.trummer-goedl@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VALIDOGEN at PepTalk 2020 for other information.
Click on VALIDOGEN GmbH to contact the company directly.
Click on UNLOCK PICHIA for further information on Pichia pastoris production toolbox .

VALIDOGEN’s Roland Weis will help show how UNLOCK PICHIA is the key to its broad expression

VALIDOGEN’s Roland Weis will help show how UNLOCK PICHIA is the key to its broad expression

Pichia pastoris protein production toolbox  UNLOCK PICHIA allows protein production to profit (among other tools) from an extended portfolio of helper factors acting at multiple sites within the production host. Combining all three helper factors in one expression construct led to a 3.5-fold enhancement of product yield

Pichia pastoris protein production toolbox

UNLOCK PICHIA allows protein production to profit (among other tools) from an extended portfolio of helper factors acting at multiple sites within the production host. Combining all three helper factors in one expression construct led to a 3.5-fold enhancement of product yield


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN presenting industrial protein production tools at ESIB 2019


VALIDOGEN presenting industrial protein production tools at ESIB 2019


Druck

PRESS RELEASE | VALIDOGEN GmbH

NOVEMBER 13, 2019

Raaba – Grambach, Austria: Protein expression specialist VALIDOGEN will be a high profile presence as sponsor at the fourth European Summit of Industrial Biotechnology (ESIB) in Graz, Austria next week (18 – 21 November).

VALIDOGEN will use the conference to communicate its advanced capabilities in industrial protein production strain & process development.

UNLOCK PICHIA

Centerpiece of VALIDOGEN’s technology is its UNLOCK PICHIA protein production toolbox comprising of a diverse set of molecular tools and expression strategies for efficient recombinant protein production in Pichia pastoris. The toolbox opens up multiple strategies for generating high-performance strains and production processes meeting industry requirements.

VALIDOGEN provides industrial protein production solutions ideally suited for efficient large scale manufacturing processes with low cost-of-goods. VALIDOGEN’s Pichia expression system not only enables cultivation with high volumetric productivities but also simplifies downstream processing due to efficient product secretion and low levels of endogenous proteins in the culture supernatant.

“All components of our Pichia toolbox are thoroughly characterized and full documentation is readily available to support regulatory filings for different applications of protein products including strains for the manufacture of GRAS products and strains free of antibiotic selection markers”, commented VALIDOGEN Head of Business Development, Dr. Thomas Purkarthofer. “In addition, all reagents used in the course of strain development are certified animal-origin-free and our unique 2nd generation promoter library enables safe and convenient methanol-free protein production processes without compromising process economy”, said Dr. Purkarthofer.

Enzyme Engineering

Supporting companies in product innovation, VALIDOGEN´s established high-throughput microscale strain cultivation and screening protocols can also facilitate screening and identification of improved enzyme variants. “The key advantage of using UNLOCK PICHIA for the generation of enzyme variants is that engineering is performed in the final production host without a change of the host system from primary screen to final enzyme production. In addition, application of UNLOCK PICHIA ensures production of high-value enzymes at lower manufacturing costs”, Dr. Purkarthofer noted.

About VALIDOGEN GmbH

VALIDOGEN GmbH (formerly VTU Technology), a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

VALIDOGEN is a private company and independent subsidiary of the KonValue Group.

www.validogen.com and www.unlockpichia.com.

About ESIB 2019

The European Summit of Industrial Biotechnology (ESIB) was founded in 2016 to provide a new European communication platform for industrial biotechnology, bringing together scientific topics with industrial needs and priorities, economic demands, funding resources and political aspirations in an event that combines knowledge-sharing, networking and recreation.

The fourth summit, ESIB 2019, is a three-day event opening November 18 at the Messecongress in the center of the ancient Austrian university city of Graz.

The event is organized by the Austrian Centre of Industrial Biotechnology (ACIB) with more information available at: https://www.esib.at.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VALIDOGEN at ESIB 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN presenting UNLOCK PICHIA tools at RAFT® 13 in Florida


VALIDOGEN presenting UNLOCK PICHIA tools at RAFT® 13 in Florida


Druck

PRESS RELEASE | VALIDOGEN GmbH

OCTOBER 09, 2019

Raaba – Grambach, Austria: Protein expression specialist VALIDOGEN will be a prominent contributor to the RAFT fermentation technology conference in Florida, USA, this month.

VALIDOGEN will use the highly regarded bi-annual conference to communicate the advantages of its yield-enhancing ‘UNLOCK PICHIA’ protein production toolbox to enable fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia pastoris.

Harness Pichia for your application

VALIDOGEN’s Head of Operations, Dr. Roland Weis, will contribute to the ‘Cell Factory Design & Engineering’ session on Day One of the conference (Sunday, October 27, 2019 2:00 PM – 4:30 PM) with his presentation: ‘UNLOCK PICHIA – a toolbox to maximize productivity through diversity’.

Dr. Weis will show how ‘UNLOCK PICHIA’ provides an ideal response to an industrial protein production environment in which novel product classes and current trends in protein production demand more versatile and yet robust expression systems.

Dr. Weis will tell the conference that continuous expansion and improvement of the UNLOCK PICHIA technology platform facilitates targeted debottlenecking of protein expression all the way from transcription and translation to translocation, protein folding and secretion thereby enabling the expression of more complex proteins without compromising product quality. The broad diversity of molecular tools available in VALIDOGEN’s toolbox provides solutions for different requirements in order to best meet the aims of each specific application.

Maximising yield

“Selection of best-performing clones from strain engineering approaches in microscale, i.e. 96-deep-well plates, is directly followed by cultivation in benchtop bioreactors to reconfirm screening results and at the same time gather information on growth and production behavior,” Dr. Weis says.

“Subsequent bioreactor cultivation process optimization elucidating the interplay of important process parameters such as pH-value, temperature, feeding profile as well as biomass level results in maximization of yield & quality of the target protein,” he adds.

About VALIDOGEN GmbH

VALIDOGEN GmbH (previously VTU Technology GmbH) is a leading contract research and development company, offering the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

Based on its technology platform known as UNLOCK PICHIA, VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor – made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Group.

More Information: www.validogen.com and www.unlockpichia.com.

About RAFT 2019

The biannual Recent Advances in Fermentation Technology (RAFT®) conference provides a forum for industrial and academic scientists to discuss the latest developments in fermentation as applied in research and industry.

The conference is one of a series of specialist meetings sponsored by America’s Society for Industrial Microbiology and Biotechnology. The first RAFT conference was held in San Diego in 1995 and held every two years since.

The 2019 RAFT conference (RAFT® 13) is a four day event opening October 27 at the Hyatt Regency Coconut Point hotel at Ft. Myers, Florida.

The conference will feature an exhibition, exhibitor showcases and a full program of presentations including keynote presentations on Cell Factory Design & Engineering, Big Data AI & Machine Learning, Scale-up & Tech Transfer and Continuous Manufacturing.

The event is organized by the US-based Society for Industrial Microbiology and Biotechnology (SIMB) with more information at: https://www.simbhq.org/raft/.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4000

Resources

Click on VALIDOGEN at RAFT 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN presenting UNLOCK PICHIA advantages at BIO International 2019


VALIDOGEN presenting UNLOCK PICHIA advantages at BIO International 2019


Druck

PRESS RELEASE | VALIDOGEN GmbH

MAY 28, 2019

Grambach, Austria: Protein expression specialist VALIDOGEN will once again be an important presence at the upcoming 26th BIO International Convention in Philadelphia.

VALIDOGEN will use the high prestige event to communicate the advantages of its yield-enhancing UNLOCK PICHIA protein production toolbox to enable fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia pastoris.

Founded as VTU Technology, VALIDOGEN will be headed by Roland Weis, Head of Operations. “For us the BIO International Convention is one of the most important partnering events to be found anywhere in the world and a key opportunity to find collaborators for our innovative Pichia pastoris protein production technologies,” said VALIDOGEN’s Head of Business Development, Thomas Purkarthofer

The UNLOCK PICHIA advantage

UNLOCK PICHIA, VALIDOGEN’s exclusive Pichia pastoris protein expression technology is based on its unique PAOX1 promoter library for methanol-induced and methanol-free protein production combined with a diverse set of different platform strains for different applications and an exclusive yield-enhancing helper factor collection. Applied by VALIDOGEN’s sophisticated team, this cutting-edge platform facilitates the delivery of unparalleled expression levels with more than 20 g/L of secreted protein (and even more than 30 g/L in a recent case, the highest titer for Pichia reported to date) within a few weeks development time.

A continuous expansion and improvement of the UNLOCK PICHIA platform is aiming of speeding up targeted debottlenecking of protein expression all the way from transcription and translation to translocation, protein folding and secretion.

VALIDOGEN’s capabilities range from fast track feasibility studies to comprehensive Pichia pastoris expression strain development as well as development and optimization of an entire production process (fermentation & DSP). Processes developed in VALIDOGEN’s labs were transferred successfully to customers and have been shown to be robust and scalable facilitating the sound and straightforward implementation in large-scale production facilities.

Safe, clinically validated, well-characterized and CMC-ready Pichia pastoris protein production strains and processes

VALIDOGEN will use BIO’s advanced partnering platforms to show how customers benefit from the economic advantages of enhanced biologics production arising from UNLOCK PICHIA.

All components of VALIDOGEN´s Pichia toolbox, which has already been used to produce proteins for clinical studies, are thoroughly characterized and full documentation is readily available to support regulatory filings for biologic candidates.

Pichia is well suited to produce a wide range of biopharmaceuticals from cytokines, growth factors, hormones, serum proteins to fusion proteins (Fc-and albumin fusion), protein scaffolds, vaccine antigens, enzymes or allergens and antibody-derived fragments. Especially therapeutics fused to HSA and recombinant single domain antibodies known as sdAbs, VHHs or Nanobodies® can be successfully expressed at high levels & quality.

Although belonging to the microbial expression hosts, Pichia based protein production is also well suited for glycosylated proteins. The UNLOCK PICHIA platform can be efficiently combined with Pichia Glycoswitch® enabling the boosted production of homogeneous and uniform glycoproteins.

About VALIDOGEN GmbH

VALIDOGEN GmbH (previously VTU Technology GmbH) is a leading contract research and development company, offering the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

Based on its technology platform known as UNLOCK PICHIA, VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor – made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Group.

More Information: www.validogen.com and www.unlockpichia.com.

About BIO International 2019

The 26th BIO International Convention (BIO 2019) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

BIO International 2019 moves to Philadelphia PA as a four -day event opening June 3 at the Pennsylvania Convention Center.

The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: https://convention.bio.org/.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4000

Resources

Click on VALIDOGEN at BIO International 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN presenting advanced protein production tools at RPP conference in Crete


VALIDOGEN presenting advanced protein production tools at RPP conference in Crete


PRESS RELEASE | VALIDOGEN GmbH

APRIL 10, 2019

Grambach, Austria: Protein expression specialist VALIDOGEN will be a prominent presence as sponsor and presenter at the recombinant protein production (RPP) 2019 conference on the Greek island of Crete.

VALIDOGEN, formerly VTU Technology, will be presenting advantages of its ‘UNLOCK PICHIA’ toolbox as a competitive element in advanced recombinant protein production.

UNLOCK PICHIA

Dr. Roland Weis, VALIDOGEN’s Head of Operations, will contribute to the ‘Recombinant protein production processes at industrial scale’ session on Day Three (11.20-11.40 hrs, April 26) with his presentation on ‘Productivity through diversity – a protein production toolbox to UNLOCK PICHIA’.

“Novel product classes and current trends in biopharma production ask for versatile and yet robust expression systems. Our answer is a yield-enhancing protein production toolbox, ‘UNLOCK PICHIA’, that enables fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia,” Dr. Weis explained.

AOX-1 promoter library

His presentation will show how VALIDOGEN’s Pichia toolbox including an exclusive AOX1-promoter library (with and without methanol induction) leverages gene/protein-customized expression which translates into high-level production strains already identified from high-throughput cultivation and screening in microscale format.

Due to this robust deep-well plate cultivation method, rapid and most importantly reliable transfer to bioreactors and further scale-up is ensured, which is manifested by production campaigns in up to 100,000L scale with a strain as well as a cultivation process developed with VALIDOGEN.

Clearing expression bottlenecks

Continuous expansion and improvement of its technology platform facilitates the targeted debottlenecking of protein expression all the way from transcription and translation to translocation, protein folding and secretion, thereby facilitating the expression of more complex proteins without compromising product quality.

Dr. Weis will share results from showcase productions as well as dedicated industrial projects, spanning the fields of biopharma and diagnostic products over industrial enzymes and enzyme engineering via directed evolution.

About VALIDOGEN GmbH

VALIDOGEN GmbH (previously VTU Technology), a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company.

More Information: www.validogen.com and www.unlockpichia.com.

About RPP 2019

The RPP conference is a biennial event that offers a comprehensive overview of current challenges and innovative solutions in recombinant protein production, focusing on the comparative physiology of microbial and higher eukaryotic platforms for protein production.

The 2019 RPP conference (RPP10) is a four-day event opening April 24 at the Creta Maris Hotel at Hersonissos near Heraklion, Crete.

The conference will build on the successes of previous meetings, which have attracted steadily increasing numbers of researchers from both academia and the bioprocessing industry. The meeting will address major areas and emerging trends in industrially relevant recombinant protein production, including host physiology under bioprocess conditions, cell engineering, industrial-scale processes and new-format or difficult to express proteins.

The event is jointly organized by the European Federation of Biotechnology (EFB) Microbial Physiology Section in partnership with the Federation of European Microbiological Societies (FEMS). Further information at: http://www.efbiotechnology.org/RPP.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VALIDOGEN at RPP 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN to copresent with Boehringer Ingelheim at BPI West 2019


VALIDOGEN to copresent with Boehringer Ingelheim at BPI West 2019


Druck

PRESS RELEASE | VALIDOGEN GmbH

FEBRUARY 27, 2019

Raaba-Grambach, Austria: – Protein expression specialist VALIDOGEN will be a leading contributor to the scientific debate at the upcoming BioProcess International US West Coast (BPI West) meeting in Santa Clara, California.

End-to-end process development

VALIDOGEN, formerly VTU Technology, will be represented by Iskandar Dib, Head of Analytics and DSP who will join Stefan Krahulec, Senior Manager Technology & Innovation at Boehringer Ingelheim RCV to deliver a joint presentation on “Best practice model for collaborative end to end process development and manufacturing using Pichia pastoris.

Their presentation will form part of BP West’s Pre-Conference Symposium on Microbial Manufacturing on Monday, March 11, (3:30 – 4:00 pm).

Iskandar and Stefan will also participate in the “Thought Leaders Discussion: Where Is, Microbial Production Going?” on March 11, (9:30 – 10:00 am). Topics to be discussed will cover the role of microbial hosts in the bioproduction space, technologies and product advances that will change the market for microbial production and drive industry away from traditional CHO platforms as well as the development of microbial platform approaches.

VALIDOGEN will be present throughout the summit to discuss the advantages of its yield-enhancing “UNLOCK PICHIA protein production toolbox” to enable fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia pastoris.

About VALIDOGEN GmbH

VALIDOGEN GmbH (previously VTU Technology) is a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.

Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Group.

More Information: www.validogen.com and www.unlockpichia.com.

About BioProcess International US West 2019

The BioProcess International US West (BPI West) is one of an international series of BioProcess events that aim to provide leading phase-based bioprocessing knowledge sharing focused on advancing promising biologic developments towards commercial success.

BPI West 2019 is a four-day event opening March 11 at the Santa Clara Convention Center in California.

The meeting will feature e full program of sessions with presentations from leading scientists, engineers and regulators working across the entire bioprocessing spectrum, including Dr. Jerry Murry, Vice President of Amgen, Dr. Rahul Singhvi, Chief Operating Officer of Takeda Vaccines, Inc., Dr. Jens Vogel, President & CEO of Boehringer Ingelheim Fremont Inc. and Dr. Arifa Khan, Supervisory Microbiologist at the US Food & Drug Administration.

The conference is constructed around six scientific tracks covering Viral Safety, Early Stage Process Development, Late Stage PD, Commercial Manufacturing and Single-Use/Flexible Facilities.

The event is organized by KNECT 365 with further information at: https://lifesciences.knect365.com/bpi-west/.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VALIDOGEN at BPI West 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VALIDOGEN presenting new responses to Pichia production challenges at PepTalk 2019


VALIDOGEN presenting new responses to Pichia production challenges at PepTalk 2019


Druck

PRESS RELEASE | VALIDOGEN GmbH

DECEMBER 18, 2018

Grambach, Austria: – Protein expression specialist VALIDOGEN (formerly VTU Technology) will be a leading contributor to January’s Protein Science Week (PepTalk 2019) event in San Diego, California.

VALIDOGEN will be represented by Iskandar Dib, Head of Analytics and DSP and Roland Weis, its Head of Operations.

Dr. Dib will deliver a presentation on “Productivity through Diversity – a Protein Production Toolbox to UNLOCK PICHIA”.

This will be part of the PepTalk “Engineering Genes, Vectors, Constructs, and Clones” stream, taking place on Monday, 14 January, between 5.30pm and 6.00pm

Meeting current biopharma production challenges

The presentation will note that novel protein classes and current trends in biopharma production require more versatile and yet robust expression systems. VALIDOGEN’s answer is a yield-enhancing protein production toolbox known as UNLOCK PICHIA enabling fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia.

Dr. Dib will show how UNLOCK PICHIA can facilitate the targeted debottlenecking of protein expression all the way from transcription and translation to translocation, protein folding and secretion.

About VALIDOGEN GmbH

VALIDOGEN GmbH, a leading Austrian contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.

VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

More Information: www.validogen.com and www.unlockpichia.com.

About PepTalk 2019

The Protein Science Week known as PepTalk is one of the largest annual gatherings of protein science researchers in the world. Now, in its 18th year, PepTalk features renowned speakers from academia, biotech and pharma who bring global expertise and perspective to the forefront.

An international audience of more than 1,300 participants convene for intensive learning and networking to discover new opportunities, apply alternative solutions, and develop promising partnerships.

PepTalk 2019 is a five-day event opening January 14, 2019 at the Hilton San Diego Bayfront hotel.

The event is organized by the CHI Division of Cambridge HealthTech Institute, with further information at: https://www.chi-peptalk.com.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VALIDOGEN at PepTalk 2019 for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VTU Technology is now VALIDOGEN


VTU Technology is now VALIDOGEN


Druck

PRESS RELEASE | VALIDOGEN GmbH

OCTOBER 22, 2018

Change of Company Name: VTU Technology is now VALIDOGEN
UNLOCK PICHIA – A technology from VALIDOGEN

Raaba-Grambach, Austria: – VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.

Founded in 2008, VTU Technology has become a recognized player in the field of Pichia pastoris based protein production and will now continue its business as VALIDOGEN, a private company and independent subsidiary of KonValue Group. VALIDOGEN will continue to be a leading partner for the development of microbial protein production strains and processes“, said Dr. Michael Koncar, founder and CEO of VALIDOGEN and KonValue Group.

UNLOCK PICHIA – a technology from VALIDOGEN

In connection with the company’s name change, VALIDOGEN introduces UNLOCK PICHIA as a label for its established, exclusive Pichia protein production technology. UNLOCK PICHIA is known as the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production.

The company has been continuously working on the optimization and expansion of its Pichia toolbox, which is unmatched in terms of genetic diversity. UNLOCK PICHIA addresses challenges all the way from transcription and translation to translocation, protein folding and secretion and facilitates the expression of more complex proteins thus maximizing yields without compromising product quality.

About VALIDOGEN GmbH

VALIDOGEN, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production known as UNLOCK PICHIA. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries. VALIDOGEN will be a private company and independent subsidiary of KonValue Group.

More Information: www.validogen.com, www.unlockpichia.com.

Media Contacts

Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Email: thomas.purkarthofer@validogen.com
Tel.: +43 316 4009 4017

Resources

Click on VTU Technology is now VALIDOGEN for other information.
Click on VALIDOGEN GmbH to contact the company directly.


Supplier Information
Supplier: VALIDOGEN GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.validogen.com


VTU Technology brings full range Pichia protein production toolbox to CPhI Madrid


VTU Technology brings full range Pichia protein production toolbox to CPhI Madrid


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

SEPTEMBER 28, 2018

Grambach, Austria: – Protein expression specialist VTU Technology will present its enhanced Pichia pastoris protein production toolbox on its return to Europe’s largest pharmaceutical trade fair, CPhI Worldwide in Madrid in October.

VTU will exhibit at Booth 3D73 as part of the Life Science Austria stand at IFEMA, Madrid, showcasing its broadest-yet Pichia toolbox for competitive protein and glycoprotein production. The world-leading VTU Pichia pastoris recombinant expression platform offers higher efficiency production of a wide range of protein candidates for different applications.

VTU has been a consistent presence at CPhI Worldwide since 2009. Once again its CPhI team will be led by Head of Business Development Dr. Thomas Purkarthofer.

Protein productivity challenges

“CPhI provides one of the world’s best platforms to reach out to potential customers from all over the world,” commented Dr. Purkarthofer.

“Producing high-quality proteins for therapeutic applications at high yields is a crucial objective for protein manufacturers,” he noted.

“The bioprocessing industry faces many challenges in reaching its goals of increased efficiency and improved economics in protein production. Although considerable progress has been made over the past 20 years to raise the productivity and robustness of manufacturing processes for biopharmaceuticals, the cost and complexity of their development remain high,” said Dr. Purkarthofer.

Combined advantages

“From the list of therapeutic protein approvals, two pre-eminent hosts have so far dominated the field of recombinant protein expression: the bacterial Escherichia coli (E. coli) system and mammalian cell lines, such as Chinese hamster ovary (CHO) cells. Combining the advantages of these, the versatile yeast Pichia pastoris is emerging to become a competitive alternative for biomanufacturing. VTU´s Pichia system meets so far unfilled productivity needs through diversity, high productivity & product quality while maintaining flexibility & speed,” he concluded.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks’ development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company.

More information: www.vtu-technology.com and www.vtu.com.

About CPhI Worldwide 2018

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.

Now in its 29th year, the 2018 event is a three-day event opening October 9 at IFEMA, Feria de Madrid, Spain, which last hosted the event in 2015. CPhI Worldwide 2018. CPhI Worldwide includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events. Together, they are expected to attract a record 45,000 delegates along with 2,500 exhibiting companies from 153 countries.

New for 2018, the Expo will feature bioLIVE, a new specialized exhibition focusing on the biopharmaceutical industry.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: https://www.cphi.com/europe/.

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at CPhI Worldwide 2018 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology to show 25th BIO International how to Unlock Pichia


VTU Technology to show 25th BIO International how to Unlock Pichia


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

MAY 24, 2018

Grambach, Austria: – Protein expression specialist VTU Technology will show potential partners at June’s high prestige BIO International Convention in Boston how to unlock the advantages of its leading-edge protein production platform, its Pichia pastoris recombinant expression technology.

Safe, clinically validated, well-characterized and CMC-ready Pichia pastoris protein production strains and processes for biopharmaceutical manufacturing

VTU will demonstrate how biopharma companies benefit from VTU´s CMC compliant technology platform for the safe and effective production of therapeutic candidates.

Pichia pastoris has been approved by major regulatory authorities for the production of biopharmaceuticals and, on top of that, several appealing features render the VTU Pichia platform well suited for the production of biologics. All components of VTU´s Pichia toolbox, which has already been used to produce proteins for clinical studies, are thoroughly characterized and full documentation is readily available to support regulatory filings for biologic candidates.

Furthermore, Pichia based protein production is no longer limited to non-glycosylated proteins. VTU offers boosted glycoprotein production by combining VTU´s Pichia technology with Pichia Glycoswitch®. Pichia Glycoswitch® enables the production of homogeneous and uniform glycoproteins with Man5- or other human-like glycoforms. The Picha GlycoSwitch® system is based on yeast strains that have been engineered to perform specific glycosylation steps at high fidelity.

Unlocking Pichia power

The VTU presence at the convention will be led by Head of Business Development, Dr. Thomas Purkarthofer, along with Roland Weis, Head of Operations.

“Once again, this important convention provides us with a great opportunity to reach out to a wide range of people and companies dealing with recombinant protein and biologics production, ranging from small biotechs to big pharma, diagnostics producers, along with food/feed, agro and chemical industries,” said Dr. Purkarthofer.

“We will show visitors how VTU addresses the multiple aspects of protein expression by increasing genetic diversity. A broad set of helper factors, platform strains and new concepts abolishes bottlenecks in transcription, translation, translocation, protein folding and secretion,” he added.

“Since our foundation in 2008, we have been continuously optimizing and expanding our Pichia technology to generate an unparalleled spectrum of exclusive tools and strategies to meet highly specific expression needs, now making it the broadest and most powerful Pichia pastoris protein production platform available anywhere,” Roland Weis noted.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

More information: www.vtu-technology.com and www.vtu.com.

About BIO International 2018

The 25th Anniversary BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

BIO International 2018 returns to Boston MA as a four -day event opening June 4 at the waterfront Boston Convention and Exhibition Center (BCEC). The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.

A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.

The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/.

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at BIO International 201 for other information.
Click on VTU Technology to contact the company directly.
Click on Pichia pastoris for more on proteins and processes.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology bringing Pichia advances to BPI Europe


VTU Technology bringing Pichia advances to BPI Europe


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

APRIL 18, 2018

Grambach, Austria: – Protein expression specialist VTU Technology is headed for the influential BioProcess International European Summit, BPI Europe, in Amsterdam to share latest advances in its Pichia pastoris recombinant expression technology.

These include new technology developments to VTU’s growing protein production toolbox that offer rich potential for production of biopharmaceuticals.

Safe, clinically validated, well-characterized and CMC-ready Pichia pastoris protein production strains and processes for biopharmaceutical manufacturing.

VTU will demonstrate how biopharma companies benefit from VTU´s CMC compliant technology platform for the safe and effective production of therapeutic candidates.

Pichia pastoris has been approved by major regulatory authorities for the production of biopharmaceuticals and, on top of that, several appealing features render the VTU Pichia platform well suited for the production of biologics.

All components of VTU´s Pichia toolbox, which has already been used to produce proteins for clinical studies, are thoroughly characterized and full documentation is readily available to support regulatory filings for biologic candidates.

Furthermore, Pichia based protein production is no longer limited to non-glycosylated proteins. VTU offers boosted glycoprotein production by combining VTU´s Pichia technology with Pichia Glycoswitch®. Pichia Glycoswitch® enables the production of homogeneous and uniform glycoproteins with Man5- or other human-like glycoforms. The Picha GlycoSwitch® system is based on yeast strains that have been engineered to perform specific glycosylation steps at high fidelity.

Unlocking new production solutions

VTU will be represented at BPI Europe by its Head of Downstream and Analytics and Principal Scientist and Principal Scientist, Dr. Iskandar Dib, who is expert in up- and downstream process development applying DoE tools for process understanding.

Iskandar is accepting requests through the partnering system or by email (see below) from anyone looking to discuss advanced recombinant protein production solutions in Amsterdam.

“I’ll be happy to discuss how we provide unique solutions through an increase in genetic diversity. VTU Technology’s platform stands out due to its potential for expression optimization and debottlenecking with respect to many aspects of protein expression all the way from transcription and translation to translocation, protein folding and secretion thus maximizing yields without compromising product quality,” Iskandar Dib added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com.

About BPI Europe 2018


The BioProcess International European Summit (BPI Europe) is one of the world’s largest events dedicated to bioprocessing, highlighting the sciences, technologies and partners needed to accelerate promising biologics to market.

BPI Europe 2018 is a three-day event opening April 23 at the RAI Conference Center in Amsterdam.

The conference is expected to attract more than 900 scientists and executives representing some 275 companies and organizations working across the entire bioprocessing spectrum. The co-located exhibition will feature more than 160 leading companies.

The event is organized by Knect365 with more information at: https://lifesciences.knect365.com/bpieurope/.

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at BPI Europe for other information.
Click on VTU Technology to contact the company directly.
Click on Pichia pastoris platform for detailed briefing.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology attending leading events worldwide


VTU Technology attending leading events worldwide


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

MARCH 01, 2018

Grambach, Austria: – Protein expression specialist VTU Technology is headed for influential events on both sides of the Atlantic during March 2018 to present different aspects of its Pichia pastoris recombinant protein production technology.

At all three events, VTU will reveal its latest advances and emerging applications of its exclusive Pichia pastoris protein expression toolbox allowing the time-saving generation of high performance expression strains and economically viable protein production processes for the competitive manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Halle Recombinant Proteins Conference

The program begins on March 8, when VTU will attend the two-day 6th Halle Conference on Recombinant Proteins in Halle/Salle, Germany.

During the first day of the conference, VTU´s Head of Downstream and Analytics, Dr. Iskandar Dib will give a presentation: ‘Unlock Pichia – novel strategies and molecular tools to enhance protein expression’ during the morning session on New Expression Technologies”.

BIO-Europe Spring 2018

Four days later, VTU Technology Head of Business Development, Dr. Thomas Purkarthofer will lead the company’s team to Amsterdam to be present at the BIO-Europe Spring partnering conference.

VTU Technology is now accepting requests by email (see below) or via BIO-Europe’s partneringONE platform from anyone looking to discuss advanced recombinant protein production solutions with Thomas Purkarthofer in Amsterdam.

BioProcess International, San Francisco

Five days after the Bio-Europe event ends, VTU will travel to the US West Coast for the BioProcess International Conference & Exhibition in San Francisco., California, to provide delegates with insights into VTU´s latest technology developments.

Unlock Pichia – Broadest Pichia protein production platform

“We will be able to show how we provide unique solutions through an increase in genetic diversity. VTU Technology’s platform stands out due to its potential for expression optimization and debottlenecking with respect to many aspects of protein expression all the way from transcription and translation to translocation, protein folding and secretion thus maximizing yields without compromising product quality,” he added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com

About Halle Conference on Recombinant Proteins

The Halle Conference on Recombinant Proteins provides a unique platform for the exchange of latest scientific and technological findings, know-how and expertise between scientists from academia and industry.

Presenters from Pharma industry, Biotech industry and Academia talk about latest developments of protein-based therapeutics covering new formats, modifications, manufacturing, formulation and analytics.

The 2018 Conference is a two day event, opening March 8, 2018, at the German Academy for Sciences Leopoldina, in association with Martin Luther University in Halle-Wittenberg.

The event is organized by the University with more information available at: http://www.biochemtech.uni-halle.de/halle_conference/

About BIO-Europe Spring 2018

BIO-Europe Spring® a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

The three-day event opens on March 12 at the RAI Convention Center in Amsterdam.

Featuring EBD Group’s sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

The event is organized by EBD with more information at: https://ebdgroup.knect365.com/bioeurope-spring/

About BPI West 2018

The BioProcess International West Coast (BPI West) Summit is one America’s leading phase-based bioprocessing events for emerging biologic processes with commercial potential.

The four-day even opens March 19, 2018, at the Hilton San Francisco Union Square and will host more than 400 bioprocessing professionals from academia and industry.

The conference features four major streams on Early Stage Process Development, Late Stage Process Development, Commercial Manufacturing and Single-Use/ Flexible Facilities.

BPI West is also organized by EBD with further information at: https://lifesciences.knect365.com/bpi-west/

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology attending leading events worldwide for other information.
Click on VTU Technology to contact the company directly.
Click on Pichia pastoris platform for detailed briefing.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology to ‘unlock Pichia’ at PepTalk 2018


VTU Technology to ‘unlock Pichia’ at PepTalk 2018


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

DECEMBER 19, 2017

Grambach, Austria: – Protein expression specialist VTU Technology will be sharing insights on the keys to unlocking the power of Pichia pastoris-based protein expression at America’s Protein Sciences Week, PepTalk 2018, in San Diego.

VTU will be represented at the event by VTU´s CTO Roland Weis and principal scientist Iskandar Dib.

Iskandar Dib will participate in the “Engineering Genes and Hosts” stream on Day Two of the conference, Tuesday, January 9, delivering a presentation “Unlock Pichia – Novel Strategies and Molecular Tools to Enhance Protein Expression”.

Competitive with Pichia pastoris

Iskandar will introduce how VTU addresses the multiple aspects of protein expression by increasing genetic diversity. Applying its Pichia pastoris toolbox, VTU generates a large number of different genetic constellations thus unlocking Pichia´s potential for successful production of fully active, high quality proteins through fine-tuning of expression.

VTU’s extended molecular toolbox addresses challenges all the way from transcription and translation to translocation, protein folding and secretion and facilitates the expression of more complex proteins thus maximizing yields without compromising product quality.

The latest technology developments and versatile applications of VTU´s Pichia pastoris protein expression technology platform will be presented.

Dr. Iskandar Dib is a graduate of Graz University of Technology and the Research Center for Applied Biocatalysis. After obtaining his PhD he joined the team of VTU Technology where he now heads the DSP and Analytics department.

Dr. Dib’s areas of expertise include process development for up- and downstream processes applying DoE tools for process understanding. He is also responsible for VTU’s protein products, co-developed with a partner company.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com.

About PepTalk Protein Science Week 2018

PepTalk: The Protein Science Week is one of the largest annual gatherings of protein science researchers in the world. The conference attracts nearly 1,300 experts from academia, biotech and pharma who come together for one week of intensive learning and networking focusing on a wide spectrum of applied protein sciences with emphasis on upstream R&D engineering to downstream biologics production.

Now in its 17th year, PepTak 2018 is a five-day event that opens January 8, 2018 at the Hilton San Diego Bayfront Hotel & Conference Center.

The conference programs features keynote presentations, case studies and new unpublished data from top influential leaders in academia and industry, along with training seminars, dinner short courses and a co-located exhibition.

The event is organized by Cambridge HealthTalk (CHI) with more information available at: www.chi-peptalk.com

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at PepTalk 2018 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology bringing Pichia advances to leading European events


VTU Technology bringing Pichia advances to leading European events


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

NOVEMBER 02, 2017

Grambach, Austria: – Protein expression specialist VTU Technology will be showcasing its latest advances in exploiting its leading Pichia pastoris recombinant protein production technology at two high profile Europe events in November.

VTU Technology Head of Business Development, Dr. Thomas Purkarthofer will lead the company’s team at BIO-Europe in Berlin and a week later at the second European Summit of Industrial Biotechnology (ESIB) in the Austrian city of Graz.

In addition, Dr. Purkarthofer will present and participate in a discussion panel at ESIB on latest biopharma production technologies during the early afternoon of Day 2 (November 15).

“We look forward to returning to both these events to talk about new applications that provide fertile ground for productive partnerships for companies seeking competitive advantage,” said Dr. Purkarthofer.

Yield optimization through comprehensive production strain development

At both events, VTU will reveal new advances and emerging applications of its world-leading Pichia pastoris expression system, including new enhancements to its methanol-free protein production technology with productivity records of 20 g/l of secreted protein in supernatant in Pichia.

“With the advances we’ve made since autumn 2016, we can show customers and potential partners an even broader and more powerful protein production platform, with astonishing protein yields achieved recently,” he added.

“VTU´s yield optimization & strain development program is based on the application of a large number of genetic elements from VTU´s broad Pichia pastoris toolbox facilitating optimized fine-tuning of gene expression and enhanced production of high-quality proteins,” Dr. Purkarthofer explained.

VTU Technology is inviting anyone looking for advanced recombinant protein production solutions to contact the company via BIO-Europe’s partneringONE platform to arrange face-to-face meetings with Dr. Purkarthofer in Berlin or via ESIB’s Matchmaking Event for meetings in Graz.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastorisexpression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com.

About BIO-Europe 2017

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2017 is a three-day event opening November 6 at Berlin’s City Cube conference center.

BIO-Europe has formed the launch pad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2017 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: https://ebdgroup.knect365.com/bioeurope/.

About ESIB 2017

The European Summit of Industrial Biotechnology (ESIB) was founded in 2016 to provide a new European communication platform for industrial biotechnology, bringing together scientific topics with industrial needs and priorities, economic demands, funding resources and political aspirations in an event that combines knowledge-sharing, networking and recreation.

The second summit, ESIB 2017, is a three-day event opening November 14 at the Messecongress in the center of the ancient Austrian university city of Graz.

The event is organized by the Austrian Centre of Industrial Biotechnology (ACIB) with more information available at: https://esib.at/.

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at BIO-Europe and ESIB 2017 for other information.
Click on VTU Technology to contact the company directly.
Click on Pichia pastoris platform for detailed briefing.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology brings protein expression to CPhI


VTU Technology brings protein expression to CPhI


VTU Technology 150 x 56

Press Release | VTU Technology GmbH

OCTOBER 03, 2017

Grambach, Austria: – Protein expression specialist VTU Technology will present its wide-ranging Pichia pastoris protein production toolbox when it makes its debut as an exhibitor at Europe’s largest pharmaceutical trade fair, CPhI Worldwide in Frankfurt in late October.

VTU’s stand at Booth 41G30 will form part of the Austrian Pavilion at Messe, Frankfurt.

VTU’s Head of Business Development Dr. Thomas Purkarthofer, will lead the team at CPhI Worldwide, where it will present latest advances and applications of its world-leading Pichia pastoris recombinant production platform for higher efficiency production of a wide range of recombinant protein candidates.

The team will also use the event´s partnering systems to reach out to new collaborators from different industries such as biopharmaceutical, food & feed, diagnostics, chemical and agro-industry.

“Our experience over recent years has confirmed for us how important it is to meet our existing and potential customers face to face,” said Dr. Purkarthofer.

VTU offers customized high-performance protein production strains and offer straightforward cultivation & purification process development and optimization services paired with seamless technology transfer. Preparation and characterization of microbial cell banks and development of high-value enzymes through enzyme engineering services complement VTU´s broad service portfolio.

VTU´s Pichia technology is being used to produce numerous commercial proteins in each case meeting the demands of different regulatory authorities. All components of VTU´s Pichia toolbox are animal-origin-free and thoroughly characterized and full documentation is readily available to support regulatory filings.

“With the advances we’ve made during the past years, we can showcase even more powerful Pichia pastoris applications, including enhancements to our glycoprotein production package by combining our proprietary Pichia pastoris production platform with RCT´s Pichia GlycoSwitch system enabling boosted production of tailored glycoproteins,” Dr. Purkarthofer said.

High productivity

“VTU Technology provides industrial protein production solutions ideally suited for efficient large scale manufacturing processes with exceptionally high yields leading to low cost-of-goods,” Dr. Purkarthofer noted.

“VTU Pichia not only enables high volumetric productivities but also simplifies downstream processing due to efficient product secretion and low levels of endogenous proteins in the culture supernatant,” he added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com

About CPhI Worldwide 2017

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors networking opportunities with potential international pharmaceutical partners and collaborators, as well as latest industry insights.

Now in its 28th year, CPhI 2017 is a three-day event opening October 24 at the Messe Frankfurt exhibition center. Last year’s event in Barcelona attracted some 42,000 delegates and more than 2,500 exhibitor companies from 155 countries worldwide.

CPhI Worldwide is held alongside four other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, InnoPack pharmaceutical packaging and a new addition, the FDF show for Finish, Dosage and Formulations, bringing together every aspect of the finished dosage supply chain.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/.

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at CPhI Worldwide 2017 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology’s new website unlocks Pichia toolbox


VTU Technology’s new website unlocks Pichia toolbox


VTU Logo

Press Release | VTU Technology GmbH

JUNE 21, 2017

Grambach, Austria: Protein expression specialist VTU Technology has launched a re-engineered website that showcases multiple elements of its world-leading Pichia pastoris recombinant expression technology and protein production toolbox.

The redesigned VTU site allows browsers to explore key aspects of the Pichia toolbox, including VTU’s core technology of exclusive AOX1 promoter libraries for fine-tuned methanol-inducible or methanol-free protein production.

Building on Pichia´s inherent potential, VTU has established an exclusive yield-enhancing protein production platform that stands out from competitors in respect of diversity of expression tools and expression strategies.

Fine-tuned protein expression

The site now explains how VTU is able to unlock and boost protein production of fully active, high quality proteins.

Diversity of application is enhanced through proprietary expression techniques that enhance co-expression helper factors, further fine tuned by VTU´s promoter library to enhance product yields and quality.

Combined with high-throughput combinatorial cultivation and screening techniques, VTU is able rapidly and reliably to identify and generate high-level production strains meeting protein quality and productivity requirements.

Glycoengineering tools & half-life extension

The website also explores VTU’s glycoengineering tools that enable homogenous glycoprotein production through Pichia Glycoswitch® combined and boosted by VTU Pichia.

Half-life extension on biopharmaceuticals and biobetters, aided by fusion to human serum albumin(HSA) produced with VTU´s Pichia pastoris toolbox can be secreted very efficiently (5-20 g/l) resulting in reduced production costs at the same time increasing the profitability of a therapeutic product and maintaining quality.

The website also presents VTU’s extended portfolio of services, such as time-saving protein expression studies, comprehensive strain development, bioprocess development, protein purification & DSP development, cell banking as well as enzyme engineering.

The new site also incorporates full search function and offers more direct access to contact info, downloads and news updates, currently headed by VTU’s appearance at the upcoming BIO International Convention in San Diego, California.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu.com and www.vtu.com

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology rolls out new website for other information.
Click on VTU Technology to contact the company directly.
Click on www.vtu-technology.com to see English language version


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology presenting Pichia production opportunities at BIO International


VTU Technology presenting Pichia production opportunities at BIO International


VTU Logo

Press Release | VTU Technology GmbH

MAY 24, 2017

Grambach, Austria: Protein expression specialist VTU Technology will connect with scores of potential partners at the big BIO International Convention in San Diego next month to present unique production advantages for its innovative Pichia pastoris recombinant expression technology.

These include the use of VTU´s well-established Pichia pastoris protein production toolbox to facilitate competitive development of high-quality proteins, high-productivity strains & robust and scalable bioprocesses.

Advantage Austria


VTU will exhibit at Booth 5323 in the Advantage Austria Pavilion at the San Diego Convention Center.

“For us the BIO International Convention is one of the most important partnering events to be found anywhere in the world and a key opportunity to find collaborators for our innovative Pichia pastoris protein production technologies,” said VTU’s Head of Business Development, Thomas Purkarthofer, who will be representing the company at BIO International, along with Roland Weis, Head of Operations.

Pichia protein production toolbox

“It is also a great chance for companies from all industry sectors that need recombinant protein production technologies to discover the power of VTU´s exclusive yield-enhancing Pichia protein production toolbox with its diversity of expression tools and expression strategies”, said Dr. Purkarthofer.

“We will also be presenting our proprietary AOX1 promoter library and a portfolio of platform strains that provide the genetic diversity necessary for fine-tuning of protein expression, while timely adjusted co-expression of helper proteins allows for maximization of protein production”, said Roland Weis.

“In particular, our second generation promoter variants offer more flexibility by providing high-level methanol-free protein production processes,” he explained. “Moreover, Pichia based biologics production is no longer limited to non-glycosylated proteins. VTU additionally offers boosted glycoprotein production by combining VTU´s Pichia technology with Pichia Glycoswitch®, which enables the production of homogeneous and uniform glycoproteins.”

High-throughput microscale screening

“VTU´s unique high-throughput microscale cultivation and screening expertise and protocols allow rapid analysis of thousands of Pichia strains to ensure fast and reliable identification of the best performing genetic arrangement to produce the target protein,” Mr. Weis added.

Since foundation in 2008, VTU has been continuously optimizing and expanding its Pichia technology platform to generate an unparalleled spectrum of exclusive tools and strategies to meet highly specific expression needs, leading to more flexibility in protein production.

Short timelines

These allow VTU to addresses multiple aspects of protein expression with contract services and tailor-made solutions that combine short timelines with high flexibility. Services include time-saving protein expression studies, development of industrial production strains, process development & optimization, small-scale production of non-GMP product samples as well as cell banking and enzyme engineering services.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information: www.vtu-technology.com and www.vtu.com

About BIO International

The BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

BIO International 2017 is a four -day event opening June 19 at the harbor-side San Diego Convention Center in southern California. The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.

A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.

The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology at BIO International 2017 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology presenting broadest Pichia pastoris protein production toolbox at BIO Europe Spring 2017


VTU Technology presenting broadest Pichia pastoris protein production toolbox at BIO Europe Spring 2017


VTU Technology

Press Release | VTU Technology GmbH

MARCH 14, 2017

Grambach, Austria: Protein production specialist VTU Technology will present significant advances in exploiting its leading Pichia pastoris recombinant expression technology at BIO-Europe Spring biotechnology partnering conference in Barcelona from March 20.

These include the use of VTU´s well-established Pichia protein production toolbox to facilitate high-yield production of nearly all kind of proteins in unmatched quantities and at reduced production costs.

VTU will present its productive Pichia toolbox outstanding through its broad genetic diversity significantly boosting protein yields and protein quality by fine-tuning of protein expression. Optimized tools for the humanization of Pichia´s glycosylation pathway enabling the directed production of glycoproteins with defined glycosylation profiles complement the broad toolbox.

VTU will also emphasize the advantages of its unique AOX1 based methanol-free protein production and expression processes.

VTU Technology Head of Business Development, Dr. Thomas Purkarthofer will lead the company’s presence in Barcelona, offering VTU´s broad contract services as well as out-licensing and co-development opportunities for several recombinant proteins based on the Pichia pastoris platform.

Productivity records

“We attend numerous partnering events, which provides us with a great platform to present our exclusive Pichia pastoris protein production technology and expertise to a wide range of customers from pharma-, biopharma-, food-, feed-, chemical-, agro-, cosmetic- and diagnostic sectors,” commented Dr. Purkarthofer.

“More than ever, we can show how VTU Technology’s broad Pichia pastoris protein production toolbox establishes economically viable protein production processes,” he added.

Since foundation in 2008, VTU has been continuously optimizing and expanding its Pichia technology platform to generate an unparalleled spectrum of expression tools and ingenious expression strategies to meet highly specific expression needs, leading to more flexibility in protein production.

Exclusive tools

With exclusive tools, VTU addresses the multiple aspects of protein production by providing myriad ways to meet customer´s requirements with contract services that include time-saving protein expression studies, development of industrial production strains, fermentation process development and optimization, protein sample purification and downstream process development and technology transfer. Moreover, preparation and characterization of research cell banks and high-throughput enzyme engineering services complement VTU´s broad service offerings.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts more than 420 highly qualified people working in several subsidiaries in different European countries. From 2013 to 2015, the VTU group was able to boost its turnover from 40 million euros to 72 million euros. More information: www.vtu-technology.com and www.vtu.com

About BIO-Spring 2017

The BIO-Europe Spring® Conference (BIO Spring) is the springtime counterpart to EBD Group’s flagship conference BIO-Europe®, providing life science companies with further high caliber knowledge sharing and partnering opportunities.

The 2017 Bio-Europe Spring event is a three-day event opening March 20 at the CCIB Convention Centre in Barcelona, Spain.

The BIO-Europe partnering conferences have been running since 2006 and consistently attract top international executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

More than 2,400 delegates, the majority from boardroom level, are expected to attend BIO Spring 2017, representing some 1,400 companies from over 45 countries. The event will host more than 12,500 one-to-one meetings, with some 3,500 licensing opportunities posted.

The event is organized by EBD Group with more information at: https://ebdgroup.knect365.com/bioeurope-spring

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology presenting broadest Pichia pastoris protein production toolbox at BIO Europe Spring 2017 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology revealing protein expression advances at PepTalk San Diego


VTU Technology revealing protein expression advances at PepTalk San Diego


VTU Logo

Press Release | VTU Technology GmbH

DECEMBER 13, 2016

Grambach, Austria: Protein expression specialist VTU Technology will use the 2017 PepTalk Protein Science Week conference in San Diego, California to reveal significant advances in enhancing the expression of biotherapeutic proteins in microbial systems, using their Pichia pastoris platform.

VTU´s Principal R&D Manager for Process Development & Analytics, Dr. Iskandar Dib, will be presenting during the stream on Optimizing Protein Expression in Microbial Systems during the morning of Day Four of the conference.

VTU’s Chief Operating Officer, Roland Weis, will also attend the PepTalk event.

Pichia protein expression

Dr. Dib’s address, titled ‘Unleash the Yeast – Enhancing Expression of Biotherapeutics in Pichia’, shows how VTU has used a library of AOX promoter variants to express therapeutic protein candidates in Pichia pastoris at unprecedented yields often exceeding 10 g/L by finding the ideal promoter variant for each target protein.

He will demonstrate how the technology can further be used to enable cells to provide expression enhancing factors that are well-dosed and delivered just in time during expression of a target protein, thus maximizing both yield and quality.

Unprecedented yields

“This latest research underlines how our Pichia pastoris production system provides one of the most powerful and versatile recombinant protein expression and production technology platforms holding productivity records for Pichia-derived recombinant proteins,” commented VTU Technology Head of Business Development, Dr. Thomas Purkarthofer.

“Since its foundation 2008, VTU has been continuously optimizing and expanding its Pichia technology platform to generate an unparalleled spectrum of expression tools and ingenious expression strategies to meet highly specific expression needs and hence leading to more flexibility in protein production. With exclusive tools, VTU can now address multiple aspects of protein expression, providing myriad ways to reach customer goals,” added Dr. Purkarthofer.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information at: www.vtu-technology.com and www.vtu.com

About PepTalk 2017

The annual Protein Science Week, PepTalk, is one of the world’s foremost forums for protein science researchers. Now In its 16th year, PepTalk attracts nearly 1,300 experts from academia, biotech and pharma organizations in more than 40 countries. A co-located exhibition features more than 100 companies.

PepTalk 2017 is a five-day event, opening January 9 at the Hilton Bayfront Hotel in San Diego, CA.

This event will cover a wide spectrum, from upstream protein R&D science to downstream biologics. The conference programs feature keynote presentations, case studies and new unpublished data from thought leaders in academia and industry. PepTalk also features three-hour short courses focusing on topics such as Production Challenges for ADCs and Fusion Proteins, Biologics Formulation Development and NextGen Sequencing of Antibody Libraries:

PepTalk 2016 will also feature extended Training Seminars and Student Fellowships providing young researchers an opportunity to present their latest work.

The event is organized by Cambridge Healthtech Institute with more information at: http://www.chi-peptalk.com

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology revealing protein expression advances at PepTalk San Diego for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology bringing Pichia advances to BIO Europe and ESIB


VTU Technology bringing Pichia advances to BIO Europe and ESIB


VTU Logo

Press Release | VTU Technology GmbH

OCTOBER 24, 2016

Grambach, Austria: Protein expression specialist VTU Technology will be showcasing its latest advances in exploiting its leading Pichia pastoris recombinant expression technology at the high prestige BIO-Europe biotechnology partnering conference in November.

The innovative CRO will also attend the European Summit of Industrial Biotechnology (ESIB) meeting in Graz from 14-16 November.

VTU Technology Head of Business Development, Dr. Thomas Purkarthofer will represent the company at both events, offering out-licensing and co-development opportunities for several recombinant proteins based on the Pichia pastoris platform.

Recombinant proteins

“We plan to use networking opportunities and face-to-face meetings at BIO Europe to present latest advances and applications of our world-leading Pichia pastoris expression system for higher efficiency production of a wide range of biologics and other recombinant proteins,” said Dr. Purkarthofer.

“With the advances we’ve made during the past year, we can show customers and potential partners an even broader and more powerful Pichia pastoris protein production platform, with astonishing protein yields achieved over the past year,” he declared.

Tailored glycoproteins

In addition, we’ll be able to talk about some very interesting new enhancements to VTU’s recently introduced glycoprotein production services that provide fertile ground for productive partnerships for companies seeking competitive advantage,” Dr. Purkarthofer said.

“These are based on a combination of RCT´s Pichia GlycoSwitch® system boosted by our own Pichia pastoris platform for the production of tailored glycoproteins with human-like glycoforms,” he added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information at: www.vtu-technology.com and www.vtu.com

About BIO-Europe 2016


The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2016 is a three-day event opening November 7 at Cologne’s Köln Messe – Congress Center North.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

More information at: https://ebdgroup.knect365.com/bioeurope/

About ESIB 2016

The European Summit of Industrial Biotechnology (ESIB) provides a new European communication platform for industrial biotechnology, bringing together scientific topics with industrial needs and priorities, economic demands, funding resources and political aspirations in an event that combines knowledge-sharing, networking and recreation.

ESIB 2016 is a three-day event opening November 14 at the Messecongress in the center of the ancient Austrian university city of Graz.

The event is organized by the Austrian Centre of Industrial Biotechnology (ACIB) with more information available at: https://esib2016.wordpress.com

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology bringing Pichia advances to BIO Europe and ESIB for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology taking Pichia advances to CPhI Barcelona 2016


VTU Technology taking Pichia advances to CPhI Barcelona 2016


VTU Logo

Press Release | VTU Technology GmbH

SEPTEMBER 22, 2016

Grambach, Austria: Protein expression specialist VTU Technology will attend Europe’s largest pharmaceutical trade fair, CPhI 2016 in Barcelona in early October.

VTU will come to CPhI Worldwide in search of new partners and collaborators, offering its latest technology advances in exploiting its leading Pichia pastoris recombinant expression platform as well as out-licensing and co-development opportunities for several recombinant proteins.

New Pichia applications

The company’s Head of Business Development Dr. Thomas Purkarthofer, will represent VTU in Barcelona.

“We plan to use networking opportunities and face-to-face meetings to present latest advances and applications of our world-leading Pichia pastoris recombinant expression platform for higher efficiency production of a wide range of biologics and other recombinant proteins,” said Dr. Purkarthofer.

In addition, we’ll be able to talk about some very interesting new enhancements to VTU’s recently introduced glycoprotein production services – a combination of RCT´s Pichia GlycoSwitch® system boosted by VTU´s own Pichia pastoris platform for the production of tailored glycoproteins with human-like glycoforms,” Dr. Purkarthofer said.

“These provide fertile ground for productive partnerships for companies seeking competitive advantage,” he explained.

Astonishing protein yields

“Our experience over recent years has confirmed for us how important it is to meet our existing potential customers face to face,” said Dr. Purkarthofer.

“With the advances we’ve made during the past year, we can show them even an broader and more powerful Pichia pastoris protein production platform, with astonishing protein yields achieved in recent months,” he added.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information at: www.vtu-technology.com and www.vtu.com

About CPhI Worldwide 2016

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitor opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.

Now in its 27th year, the 2016 fair is a three-day event opening October 4 at the Fira de Barcelona exhibition center. Last year’s event in Madrid attracted some 36,000 delegates and 2,500 exhibitor companies from more than 150 countries worldwide.
The CPhl Worldwide show is being held alongside three other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events.

More information at: http://www.cphi.com/europe/

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology taking Pichia advances to CPhI Barcelona 2016 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology bring out licensing opportunities to BIO-International 2016


VTU Technology bring out licensing opportunities to BIO-International 2016


VTU Logo

Press Release | VTU Technology GmbH

JUNE 01, 2016

Grambach, Austria: – Protein expression specialist VTU Technology will be returning to San Francisco with the huge BIO-International Convention early next week.

VTU will use this year’s appearance to showcase its latest advances in exploiting its world-leading Pichia pastoris recombinant expression platform for higher efficiency production of a wide range of biological protein candidates.

VTU will be a prominent presence in the Austrian Pavilion (Booth 2417) at BIO-International, which the company has attended regularly since 2008.

Licensing opportunities

Additionally VTU will feature new enhancements to its recently developed glycoprotein production package – a combination of proprietary Pichia pastoris expression with RCT´s Pichia GlycoSwitch system that enables boosted production of tailored glycoproteins.

VTU will also use the Convention’s advanced networking facilities to seek new partners and collaborators, offering out-licensing and co-development opportunities for several recombinant proteins as well as ultra-competitive protein production processes.

Dr. Thomas Purkarthofer, Head of Business Development, and Dr. Roland Weis, Head of Operations will lead VTU’s team at BIO-International. Both will be available for meetings and one-to-one conferences using the event’s sophisticated web-based networking system.

Astonishing protein yields

“Our experience over the previous years just confirmed for us the importance of having effective face-to face meetings with partners and customers,” said Dr. Purkarthofer.

“With the advances we’ve made during the past year, we can show and even broader and more powerful Pichia pastoris protein production platform, with astonishing protein yields achieved over the past 12 months,” he added.

“These results just confirm the power of the underlying technology,” said Dr. Purkarthofer.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries. More information at: www.vtu-technology.com, www.vtu.com

About BIO-International 2016

The BIO-International® Convention is a flagship conference providing life science companies with further high caliber knowledge sharing and partnering opportunities. The convention attracts some 2,500 CEOs from the pharmaceutical and biotech industries.

The BIO-International convention has been running since 2003 and consistently attracts executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

The 2016 BIO-International Convention is a four-day event opening June 6 at the Moscone Center in downtown San Francisco. The Convention will play host to almost 4,000 exhibitors and is expected to increase visitor numbers for the tenth year in succession. More than 15,500 people, from 66 countries, attended the 2015 convention in Philadelphia.

The sophisticated One-on-One™ web-based partnering system was used to facilitate more than 29,000 meetings, involving more than 3,000 companies.

The US Biotechnology Industry Organization organizes the Convention, with more information at: http://convention.bio.org

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Email: Email: e.trummer-goedl@vtu.com
Tel.: +43 316 4009 4014

Resources

Click on VTU Technology bring out licensing opportunities to BIO-International 2016 for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


Evercyte and VTU Technology collaborate on development of recombinant media supplements


Evercyte and VTU Technology collaborate on development of recombinant media supplements


VTU Logo

Press Release | VTU Technology GmbH

MAY 24, 2016

Launch of first joint product – VEGF 165 for cell culture applications

Vienna and Grambach/Graz, Austria: – Evercyte GmbH, the leading provider of immortalized human primary-like cells and VTU Technology, the globally acting protein expression expert announced today that they have entered into a collaboration agreement on the development of recombinant media supplements for cell culture applications. The first conjointly developed recombinant product – Vascular Endothelial Growth Factor 165 (VEGF 165) has been recently launched with further targets in the pipeline.

The two companies have joined forces to develop recombinant media supplements such as growth factors and cytokines with constant high quality at attractive prices meeting today´s demand on cell culture media additives. Recombinant products will be produced by VTU based on its proprietary high-productivity Pichia technology facilitating the manufacturing of media supplements at competitive prices. Protein production processes at VTU are designed to deliver constant high quality of protein products.Precise, reproducible and relevant in-vitro cell-based assays performed by Evercyte guarantee constant high quality of each production batch. Using a proliferation assay based on continuously growing, highly differentiated endothelial cells (HUVEC/TERT2), Evercyte could show that the new product VEGF165 clearly outperforms currently available products regarding operational stability. A feature that is of utmost importance for sustainable cell culture. VEGF 165 is an important growth factor with high physiological and clinical relevance accordingly used in diverse biological in-vitro tests.

“Due to limitations in the availability of media supplements with constant product quality at reasonable prices we were seeking for interesting alternatives. Together with VTU´s expertise in recombinant protein production, we are now able to offer high performance products with constant quality and stability. We are very excited and are looking forward to the launch of further outstanding cell culture products addressing the needs of our customers”, said Dr. Regina Grillari, CTO of Evercyte. “Recombinant media supplements will be available along with our cell lines.”

“Evercyte´s expertise in the field of cell culture, its excellence in the development of cell-based assays and the existing network to the cell culture community qualifies Evercyte to be the perfect partner for the development of superior recombinant products for cell culture”, said Dr. Thomas Purkarthofer, Head of Business Development at VTU Technology. “Having Evercyte on board we are able to transform existing demands into products with improved quality parameters such as lot-to-lot consistency, product efficacy and stability.”

About Evercyte

Evercyte is the leading provider of immortalized human primary-like cells as well as novel production cell lines and is the partner of choice for innovative cell based assays in the field of pharma and biotech.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme using hTERT. Evercyte has made significant progress in expanding their catalogue of readily available cell lines which by now includes cells of renal (RPTEC/TERT1), skin (fHDF/TERT166), lung (HBEC3-KT) or endothelial (HUVEC/TERT2) origin.

Founded in 2011, the Vienna-based company successfully offers tools and the know-how necessary for the establishment of standardized high-throughput target identification and drug screening strategies, for toxicity studies, or for efficacy testing from statistically relevant numbers of donors. Visit us at: www.evercyte.com

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts more than 420 highly qualified people working in several subsidiaries in different European countries. From 2013 to 2015, the VTU group was able to boost its turnover from 40 million euros to 72 million euros. More information: www.vtu-technology.com, www.vtu.com

Media Contacts

Contact Evercyte
Dr. Eva Harreither
Head of Business Development
Muthgasse 18
A-1190 Vienna
Tel::+43 1 47654 79066
Email: eva.harreither@evercyte.com

Contact VTU Technology
Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18
A-8074 Raaba-Grambach
Tel: +43 316 4009 4017
Email: thomas.purkarthofer@vtu.com

Resources

Click on Evercyte and VTU Technology collaborate on development of recombinant media supplements for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration


VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration


VTU Logo

Press Release | VTU Technology GmbH

APRIL 27, 2016

Grambach and Vienna, Austria: – VTU Technology, the Austrian protein expression expert announced today the expansion of their global technology collaboration with Boehringer Ingelheim RCV GmbH & Co. KG, a global research-driven pharmaceutical company.

After successful completion of a first development program, followed by prolongation of the collaboration, Boehringer Ingelheim is now widening the technological scope. The collaboration includes the advancement of Boehringer Ingelheim’s E.coli expression platform in addition to the competitive optimization of Pichia pastoris platforms for the production of biopharmaceuticals.

“The intensification of our joint development program underlines the potential and capabilities of VTU Technology and our skilled and experienced team. This collaboration gives VTU certain access rights to Boehringer Ingelheim’s proprietary E.coli expression technologies broadening VTU’s range of services”, said Dr.Thomas Purkarthofer, Head of Business Development of VTU Technology.

“Widening our cooperation with VTU Technology increases our capabilities and resources for the development of microbial based biopharmaceutical processes. Including E.coli based expression systems to the existing successful cooperation will strengthen our technology leadership and add significant potential for both companies“,said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of more than 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 % of its net sales.

For more information, please visit: www.boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer

As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 25 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry. The services comprise the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle-transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the company will establish a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. With the roughly half billion euro investment Boehringer Ingelheim will also create more than 400 new jobs in the Austrian capital. The new production plant will go into operation by 2021.

More information: www.bioxcellence.com

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts more than 420 highly qualified people working in several subsidiaries in different European countries. From 2013 to 2015, the VTU group was able to boost its turnover from 40 million euros to 72 million euros.

More information: www.vtu-technology.com, www.vtu.com

Media Contacts

Contact Boehringer Ingelheim:
Mag. Inge Homolka
Communications Austria
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5 – 11
A-1121 Wien
Tel. +43-1-80105-2230
Email: ingeborg.homolka@boehringer-ingelheim.com

Contact VTU Technology:
Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18
A-8074 Raaba-Grambach
Tel: +43-316-4009-4017
Email: thomas.purkarthofer@vtu.com

Resources

Click on VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU bringing advanced protein expression to key European conferences


VTU bringing advanced protein expression to key European conferences


VTU Logo

Press Release | VTU Technology GmbH

MARCH 15, 2016

Grambach, Austria: – VTU Technology´s Head of Business Development Dr. Thomas Purkarthofer will represent VTU at two key summit meetings in Vienna and Stockholm during April.

At both events, he will be able to provide detailed information on VTU´s next generation protein expression technologies and advanced toolbox that have enabled VTU to achieve the highest protein expression productivities ever reported for Pichia pastoris – up to 35 grams per liter.

BIO-Europe Spring, Stockholm

Dr. Purkarthofer will first travel to the Swedish capital, Stockholm for the BIO-Europe Spring conference, where he will use the event’s online partnering system to arrange a series of meetings throughout the three-day event. He is hoping to discuss technology transfers and out licensing opportunities for products including e.g. Human Serum Albumin (HSA), Human Serum Transferrin (HST), HSA-fusion proteins, cell culture proteins and others.

“We’re reaching out pharmaceutical and veterinary companies, food, chemical and biotechnology companies with the potential to exploit and benefit from our versatile Pichia pastoris technology platform,” said Dr. Purkarthofer.

BioProcess International, Vienna

Five days after BIO-Europe Spring closes, Dr. Purkarthofer will travel on to Vienna, Austria, to attend the BioProcess International European Summit, to provide delegates with insights into VTU´s latest technology developments.

He will be able to unveil details of VTU’s latest achievements in developing its world-leading Pichia pastoris recombinant platform. The four-day event, billed as Europe’s Largest Bioprocessing Conference, will involve more than 450 Bioprocessing Decision Makers from some 230 Companies, including nine out of the Top 10 global biopharma players.

Dr. Purkarthofer is accepting appointments for face-to-face meetings at both events. Those wishing to meet him should email him directly at thomas.purkarthofer@vtu.com

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 25 g/L of secreted protein (recently reaching 35 g/l of secreted protein) for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology suite, an in-house expression platform which is continuously updated and expanded, is mainly based on its exclusive AOX1 promoter libraries and complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About BIOEurope Spring 2016

BIO-Europe Spring® a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

The three-day event, held at Stockholm’s Kistamässan Convention Center, opens on April 3.
Featuring EBD Group’s partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

The conference is expected to attract more than 2,300 delegates and 68 exhibitors from more than 50 countries worldwide, featuring more than 20 workshops and panels with more than 6,600 licensing opportunities posted.

The event is organized by EBD with more information at: http://www.ebdgroup.com/bes/index.php

About BioProcess International 2016

Now in its 12th year, the BioProcess International European Summit will host more than 400 bioprocessing professionals from academia and industry.

The conference features four major streams on Cell Culture & Upstream Processing, Downstream Processing, Manufacturing & Continuous Processing and Cell Line Development, along with numerous keynote speeches poster presentations, and an exhibition: all part of the conference’s mission to connect the biopharmaceutical industry with new ideas and innovations across all phases of bioprocess development.

The four-day event opens April 11 at Reed Messe Wien Congress Center, Vienna.
Informa organizes the event with more information at: http://www.informa-ls.com/event/BPI2016

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Tel: +43 316 4009 4014
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU bringing advanced protein expression to key European conferences for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU bringing latest technologies to Pichia 2016, Turkey and 4th BioproScale Symposium, Germany


VTU bringing latest technologies to Pichia 2016, Turkey and 4th BioproScale Symposium, Germany


VTU Logo

Press Release | VTU Technology GmbH

MARCH 11, 2016

Grambach, Austria: – Protein expression specialist VTU Technology will bring its leading expertise in Pichia pastoris recombinant technology to two scientific conferences next month.

Many industries are adopting protein production processes using Pichia pastoris for its high efficiency advantages. Rapid and reliable generation of high-level production strains, matching protein quantity and quality attributes, is key to success, particularly in biopharmaceuticals.

Pichia 2016 Antalya

VTU Technology is a platinum sponsor of the Pichia 2016 conference, opening April 3 in Antalya, Turkey. The meeting brings together Pichia players and researchers from around the globe to interact, present and learn more about the latest findings and new technology developments in the field of Pichia pastoris recombinant protein production.

VTU´s Chief Technology Officer (CTO) Dr. Roland Weis will chair the Bioprocess Optimization session on April 6, Day Three of the conference.

On the same day, from 10.45 to 11.15 a.m., VTU Technology’s Principal Scientist Process Development & Analytics, Dr. Iskandar Dib will moderate a panel discussion on production of biopharmaceuticals in Pichia with invited experts from industry and academia. The round table session will take a critical view on advantages and challenges of the Pichia system as compared to established and other emerging expression systems.

BioProScale Symposium, Berlin

Dr. Weis will also fly to Berlin to speak at the 4th BioProScale Symposium, which opens on April 6, even as the Antalya conference winds down. The three-day event will focus on industrial scale bioprocess intensification from process development to large-scale understanding.

On the final day of the Berlin symposium, Friday April 8, Dr. Weis will present insights from VTU’s experience of high-level protein production using Pichia: including case studies showing development paths from strain generation over bioreactor.

He will show how seamless transferability of lab-scale results to more controlled bioreactor conditions is of utmost importance.

High throughput cultivation and screening

VTU’s application of a versatile promoter library for fine-tuned expression of both target genes as well as specific or general auxiliary genes creates a diversity of expression strains that can only be analyzed in depth with a solid high throughput cultivation and screening system.

Dr. Weis will showcase how VTU´s development of such a cultivation and screening system has enabled more straightforward candidate strain selection, eliminating the need for time-consuming and laborious intermediate steps like shake flask cultivation.

VTU’s high-throughput screening platform has subjected a large number of model proteins to analysis, followed by direct transfer into bioreactors, often yielding multi g/L levels of secreted recombinant protein.

Dr. Weis will disclose details of strain generation and bioreactor production procedures for selected examples including growth factors, HSA-fusion proteins as well as enzymes.

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 25 g/L of secreted protein (recently reaching 35 g/l of secreted protein) for a wide range of biologics and other proteins. VTU Technology´s powerful Pichia pastoris protein expression technology suite, an in-house expression platform which is continuously updated and expanded, is mainly based on its exclusive AOX1 promoter libraries and complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About Pichia 2016

Pichia 2016 is the latest in a series of international conferences focusing on newest applications of Pichia pastori technology.

This four-day event opens April 6 at the Porto Bello Hotel and Resort in Antalya, Turkey.

Speakers and poster sessions will discuss the latest Pichia developments for post-translational modification, process development and the application of genome insights to improvements in productivity and look at emerging applications.

Scientific topics discussed include cell biology, protein secretion & posttranslational modification, genomic studies and genome annotations, bioprocess optimization & scale-up, molecular engineering and metabolic engineering for production of small compounds.

The Pichia series of conferences has been running since 2006, initially at three year intervals and since 2012 held every second year. Pichia 2014 was held in San Diego, California, organized by Research Corporation Technologies (RCT) and BioGrammatics, Inc.

Pichia 2016 is organized by Turkey’s Akdeniz University Food Safety and Agricultural Research Center.
More information at: http://www.pichia2016.com/en/

About BioProScale Symposium 2016

The 4th BioProScale Symposium is an annual German conference dealing with industrial scale bioprocess intensification from process development to large-scale understanding.

The three-day English language event opens April 6 at the House of Architecture at Berlin’s Technische Universität (TU).

The 2016 symposium will focus in cross-discipline contributions for a better understanding of large-scale operation and consistency in bioprocess development, including industrial-scale bioprocess operations, scale down approaches and process analytical technologies for advanced process design and comprehensive process monitoring using non-invasive sensors.

The event is organized by TU Berlin’s Department of Bioprocess Engineering, in collaboration with the Berlin Institute for Biotechnology and Fermentation (IfGB).
More information at: http://biotechnologie.ifgb.de/front_content.php?idart=214&idcat=14&lang=4

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Tel: +43 316 4009 4014
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU bringing latest technologies to Pichia 2016, Turkey and 4th BioproScale Symposium, Germany for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU bringing advanced protein expression to BIO-Europe


VTU bringing advanced protein expression to BIO-Europe


VTU Technology

Press Release | VTU Technology GmbH

OCTOBER 27, 2015

Grambach, Austria: – Protein expression specialist VTU Technology will use November’s BIO-Europe biotechnology partnering conference in Germany to recruit new partners to exploit its world-leading Pichia pastoris recombinant platform.

Dr. Thomas Purkarthofer, VTU’s Head of Business Development, will represent VTU in Munich. He will be able to provide detailed information on this next generation protein expression technology, along with other innovations and services.

Dr. Purkarthofer said he would use BIO-Europe’s PartneringONE system to arrange a series of meetings throughout the three-day event. He is hoping to discuss technology transfers and out licensing opportunities for Human Serum Albumin (HSA), Human Serum Transferrin (HST), HSA-fusion, cell culture proteins and among others.

“Alongside BIO, this is Europe’s most important Biotech partnering conference, which is why we’ve been regular attenders at BIO-Europe ever since 2009,” said Dr. Purkarthofer.

“We’re reaching out pharmaceutical and veterinary companies, food, chemical and biotechnology companies with the potential to exploit our powerful protein expression toolbox and highly versatile Pichia pastoris technology platform,” said Dr. Purkarthofer.

“Together, these have combined to enable us achieve the highest protein expression productivities ever reported – up to 35 grams per liter,” he added. Recently, VTU broke through the 20 g/l barrier in methanol-free protein processing.

Pichia pastoris protein expression excellence VTU Technology will also use BIO-Europe to present its high-speed expression strain development, fermentation process development and optimization, downstream and analytical process development and production of purified non-GMP material.
Dr. Purkarthofer confirmed that VTU’s versatile and powerful Pichia protein expression platform enables it to meet tight development timelines.

“We can deliver cost-effective and robust production processes that carry zero risk of viral or endotoxin contamination,” said Dr. Purkarthofer.

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 25 g/L of secreted protein (recently reaching 35 g/l of secreted protein ) for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries and in-house expression platform, complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About BIO-Europe 2015

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2015 event is a three-day event opening November 2 at Munich’s ICM international conference center.

BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2015 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: http://www.ebdgroup.com/bioeurope/index.php

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Tel: +43 316 4009 4014
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU bringing advanced protein expression to BIO-Europe for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology showcasing breakthrough technologies at BIO-International


VTU Technology showcasing breakthrough technologies at BIO-International


VTU Technology

Press Release | VTU Technology GmbH

MAY 26, 2015

Grambach, Austria: – Protein expression specialist VTU Technology will use the forthcoming BIO-International convention in Philadelphia to provide details of its latest technology developments and advances in its revolutionary Pichia pastoris protein production platform.

VTU is showcasing its groundbreaking Pichia technology that enables ultra-competitive production of proteins and development of economically viable protein production processes.

The platform has already yielded some of the highest protein yields ever recorded.

Tailored glycoproteins

Additionally VTU will feature its new glycoprotein production package – a combination of VTU’s proprietary Pichia pastoris protein production platform with RCT´s Pichia GlycoSwitch expression system to enable boosted production of tailored glycoproteins.

VTU will be a prominent presence in the Austrian Pavilion (Booth 2701) at BIO-International, which the company has attended regularly since 2008.

Dr. Thomas Purkarthofer, Head of Business Development, and Dr. Roland Weis, Head of Operations will lead VTU’s team at BIO-International. Both will be available for meetings and one-to-one conferences using the event’s sophisticated web-based networking system.

Powerful protein platform

“We see this event as one of the most important partnering conferences in the world for biotech companies,” commented Dr. Purkarthofer.

“Our message at this convention is very simple: that we can offer the world´s broadest and most powerful Pichia pastoris protein production platform enabling the cost-and time efficient production of biopharmaceuticals and any other recombinant proteins,” he added.

“The results that we’ve been able to achieve recently with our productivity enhancing protein production platform just confirm the power of the underlying technology,” said Dr. Purkarthofer.

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 25 g/L of secreted protein within a few weeks development time.

VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma and life science as well as in the energy industries.

More information at: /www.vtu-technology.com and www.vtu.com

About BIO-International 2015

The BIO-International® Convention is a flagship conference providing life science companies with further high caliber knowledge sharing and partnering opportunities. The convention attracts some 2,500 CEOs from the pharmaceutical and biotech industries.

The 2015 BIO-International Convention is a four-day event opening June 15 at the Pennsylvania Convention Center in central Philadelphia.

The BIO-International convention has been running since 2003 and consistently attracts executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

More than 15,500 people, from 66 countries, attended the 2014 convention in San Diego, California. The sophisticated One-on-One™ web-based partnering system was used to facilitate more than 29,000 meetings, involving more than 3,000 companies.

The Convention is organized by the US Biotechnology Industry Organization.

More information at: http://convention.bio.org

Media Contacts

Evelyn Trummer-Goedl, VTU Technology GmbH
Tel: +43 316 4009 4014
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU Technology showcasing glycoproteins breakthrough at BIO-International for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology and Biomay have signed license agreement


VTU Technology and Biomay have signed license agreement


VTU Logo

Press Release | VTU Technology GmbH

MAY 20, 2015

Biomay to apply VTU Pichia strains for the production of recombinant allergens

Grambach and Wien, Austria: – MAY 20, 2015 – VTU Technology and Biomay, two leading Austrian biotech companies, announced today, that they have entered into a licensing agreement for the production of recombinant allergens.

VTU Technology, currently offering a very broad and comprehensive Pichia pastoris expression platform, grants Biomay access to VTU´sPichia pastoris protein expression technology. Biomay, a global leader in allergy immunotherapy will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. Under the terms of the agreement, VTU Technology will receive royalties based on Biomay´s worldwide sales of the recombinant allergens.

VTU´s Pichia platform – standing out due to its diversity of expression tools and ingenious expression strategies – enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes. “VTU´s Pichia platform has already been utilized for the production of a wide range of different recombinant proteins with licenses granted to companies from diverse industries. We are very happy to extend this list of partnerships to the allergen space by our agreement with Biomay”, said Thomas Purkarthofer, Head of Business Development at VTU Technology.

“For Biomay, this technology cooperation with VTU is an excellent option for manufacturing of allergens being difficult to express,” adds Hans Huber, Chief Operating Officer at Biomay. “Thereby, we recently managed to produce and offer for sale the major allergen from ragweed pollen, Amb a 1, as a recombinant product.”

About VTU Technology


VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science.The VTU group currently counts around 370 highly qualified employees with subsidiaries in different European countries. The VTU group was able to boost its turnover from 40 million Euro to more than 60 million Euro within last year.

More information:
www.vtu-technology.com
www.vtu.com

About Biomay

Based in Vienna, Austria, Biomay was the first company worldwide to produce a broad spectrum of major recombinant allergens for research and diagnostic. Today, Biomay puts its strategic focus on specific immunotherapy of allergic diseases. Biomay’s lead product is BM32 – a recombinant-based therapeutic vaccine against grass pollen allergy, which is the most advanced candidate developed from Biomay´s proprietary peptide-carrier technology. BM32 has achieved promising results in a recently concluded Phase IIb placebo-controlled, multinational trial. Additionally, Biomay operates as a Contract Manufacturing Organisation (CMO), offering services for GMP-conform microbial-derived recombinant proteins and plasmid DNA.

More information:
www.biomay.com

Media Contacts

Thomas Purkarthofer, Ph.D., VTU Technology GmbH
Head of Business Development
Parkring 18
A-8074 Grambach
Tel: +43 316 4009 4017
Email: thomas.purkarthofer@vtu.com

OR

Hans Huber, PhD, CEO, Biomay
Lazarettgasse 19
A-1090 Wien
Tel: +43-1-7966296-100
Email: info@biomay.com

Resources

Click on VTU Technology and Biomay have signed license agreement for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology


Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology


VTU Tecnology Logo

Press Release | VTU Technology GmbH

FEBRUARY 10, 2015

Vienna, Austria and Grambach, Austria :– Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company,announced today the renewal of their global Pichia pastoris technology collaboration agreement.VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production, will be responsible for carrying out the joint development program in VTU´s facilities in close collaboration between researchers from both companies. Boehringer Ingelheim has decided to prolong their ongoing technology agreement with VTU to further strengthen Pichia´s position as a highly attractive and competitive host for the production of biopharmaceuticals.

“The ongoing commitment of Boehringer Ingelheim in our technology collaboration underlines the skills and capabilities of our great team. We are very much looking forward to new exciting developments in this fruitful collaboration”, said Dr. Thomas Purkarthofer, Head of Business Development at VTU Technology.

“We are excited about the continuation of our successful collaboration with VTU Technology. Together we established Pichia pastoris as innovative platform for the manufacture of biopharmaceuticals,” said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim. “With the renewal of our collaboration we will further expand our technological lead for Boehringer Ingelheim’s own development projects as well as for Boehringer Ingelheim BioXcellenceTM customers globally.”

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billioneuros. R&D expenditure corresponds to 19.5% of its net sales.

For more information, please visit: www.boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer

As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
More information: www.bioxcellence.com

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 22 g/L of secreted protein within a few weeks development time.VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening & cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industry. More information: www.vtu-technology.com, www.vtu.com

Media Contact

Thomas Purkarthofer, Ph.D.
VTU Technology GmbH
Tel: +43 316 4009 4017
Email: thomas.purkarthofer@vtu.com

OR

Mag. Matthias Sturm, Communications Austria
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5 – 11
A-1121 Wien
Tel. +43-1-80105-2230
Email: matthias.sturm@boehringer-ingelheim.com

Resources

Click on Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU Technology to offer unique combination of technologies for the high-level production of proteins with human-like glycosylation using PichiaGlycoSwitch®


VTU Technology to offer unique combination of technologies for the high-level production of proteins with human-like glycosylation using PichiaGlycoSwitch®


VTU Technology Logo

Press Release | VTU Technology GmbH

DECEMBER 03, 2014

Grambach, Austria: –VTU Technology announced today that it had entered into a development and commercialization agreement with Research Corporation Technologies (RCT) combining both companies´ Pichia pastoris protein production technologies. VTU Technology is now offering the combined technology suite as part of the company´s expression strain and corresponding bioprocess development contract services portfolio.

This means that RCT’s Pichia GlycoSwitch® – a new expression system for the production of glycoproteins with human-like glycosylation patterns- and VTU´s yield enhancing Pichia pastoris expression platform will henceforth be available in one package.

“This unique combination of technologies acting synergistically will greatly benefit our customers by leading to a high performance production platform for recombinant glycoproteins with superior product yields and uniform human-like glycoforms,“ said Dr. Thomas Purkarthofer, VTU’s Head of Business Development.

Exclusive promoter libraries

Under the terms of the agreement, RCT grants VTU Technology access to RCT´s Pichia GlycoSwitch® expression system for combination with VTU´s in-house high-yielding Pichia platform featuring different proprietary technologies such as AOX1 promoter libraries suited for both methanol-induced and methanol-free production. “We are delighted to offer Pichia GlycoSwitch® engineered with our broad portfolio of Pichia tools in this partnership with RCT,” commented Dr. Purkarthofer.

“I am convinced that our yield enhancing technologies will give GlycoSwitch® an exciting extra edge for the production of glycoproteins with Man5- or other human-like glycoforms”, he added.

Tailored glycosylation

“Our partnership with VTU Technology brings together two technologies that will enable customers to uniquely tailor the glycosylation of their target protein and explore new biological functions,” commented RCT’s Vice President and Chief Scientific Officer, Dr.Kurt R. Gehlsen.

“We are looking forward to working with VTU Technology to expand the potential of proteins manufactured in Pichia GlycoSwitch®”, said Dr. Gehlsen.

About Pichia

Pichia pastoris is a yeast that is widely used for recombinant protein expression. As a microbial eukaryotic organism, Pichia combines the post-translational modification systems similar to those found in mammalian cells, with the ease of use/manipulation of E. coli. Decades of processes development have been focused on efficiently growing Pichia to extremely high cell densities; and multiple generations of molecular biology tools have been created to engineer strains to produce tens of grams/liters of a recombinant protein product. Pichia can secrete high levels of properly folded, functional proteins into a simple, defined medium for easy purification. There have been more than 20,000 publications on the use of Pichia for the production of more than 5,000 proteins, with more than 70 products manufactured in Pichia on the market today. Pichia products include enzymes manufactured in 200,000-liter fermenters and two FDA-approved therapeutics.

Pichia GlycoSwitch® is a recombinant protein expression system that broadens Pichia’s applications to glycoproteins where N-linked glycosylation is important for biological function. Pichia GlycoSwitch® offers researchers the ability to control the glycosylation (sugar addition) of recombinant glycoproteins and explore the role of protein glycosylation and various glycan structures on protein function.Pichia´s typical high-mannose glycan patterns can also be eliminated to reduce immunogenicity caused by the unwanted hyperglycosylation. The Pichia GlycoSwitch® system consists of patents, strains and vectors that are useful for making proteins with a number of different human-like glycoforms.

For additional information about Pichia, please visit: http://www.pichia.com

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichiapastoris recombinant protein expression / production enabling highest productivities delivering up to 22 g/L of secreted protein within a few weeks development time. VTU Technology´s powerful Pichiapastoris protein expression technology is based on its optimized gene design and cloning strategies, proprietary AOX1 promoter libraries & in-house expression platform and high-throughput screening & cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industry. For additional information about VTU Technology, please visit: www.vtu-technology.com

About RCT

Based in Tucson, Arizona, RCT is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s technology portfolio includes platforms and tools that support the discovery, development and manufacturing of therapeutics. Current platform technologies include Pichia and E.coli protein expression systems and novel protein binding scaffolds. To learn more about RCT and its businesses, see: http://www.rctech.com and http://www.pichia.com

Media Contact

Thomas Purkarthofer, Ph.D.
VTU Technology GmbH
Tel: +43 316 4009 4017
Email: thomas.purkarthofer@vtu.com

OR

Kurt R. Gehlsen, Ph.D
Research Corporation Technologies
Tel: +1 520-748-4460
Email: kgehlsen@rctech.com

Resources

Click on VTU Technology and RCT announce partnership for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU offering powerful protein expression services and technology transfer at BIO-Europe 2014


VTU offering powerful protein expression services and technology transfer at BIO-Europe 2014


VTU Technology Logo

Press Release | VTU Technology GmbH

OCTOBER 26, 2014

Grambach, Austria: – Protein expression specialist VTU Technology will use November’s BIO-Europe biotechnology partnering conference in Germany to recruit new partners to exploit its versatile and world-leading Pichia pastoris protein expression platform.

Dr. Thomas Purkarthofer, VTU’s Head of Business Development, will represent VTU in Frankfurt. He will be able to provide detailed information on this next generation protein expression technology, along with other innovations and services such as high-speed expression strain development and fermentation-, downstream- and analytical process development and optimization.

Dr. Purkarthofer said he would use BIO-Europe’s Partnering ONE system to arrange a series of meetings throughout the three-day event. He is hoping to discuss ongoing project-& technology transfer opportunities, as well as outlicensing opportunities for Human Serum Albumin (HSA), Human Serum Transferrin (HST), HSA-fusion – and cell culture proteins.

“We’re looking to talk to organizations with needs and ideas for exploiting the powerful toolbox and highly versatile technology platform we have created for Pichia pastoris recombinant protein expression and production,” said Dr. Purkarthofer.

Broadest Pichia pastoris technology platform

Dr. Purkarthofer confirmed that VTU now possesses one of the most versatile and most powerful Pichia protein expression platforms in the world.

“This means we can deliver cost-effective and robust production processes within tight development timelines,” he added. To date several VTU customers have licensed and successfully scaled-up such processes for the manufacture of recombinant proteins with VTU´s Pichia system to volumes ranging from several hundred to more than 10,000 L.

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes yielding up to 22 g/L of secreted protein for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries and in-house expression platform, complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About BIO-Europe

The 2014 Bio-Europe event is being held on November 7-9 at the Portalhaus Messe exhibition center in Frankfurt-am-Main and marks the 20th anniversary of the event.

More than 3,000 people attended the 2013 Bio-Europe event in Frankfurt, representing some 1,800 companies and organizations from 56 countries, along with 95 exhibitors. The 2013 event also featured more than 180 presentations and 18 workshops or panels.

The event is organised by EBD Group, whose sophisticated web-based partneringONE system was last year used to facilitate almost 18,000 one-to-one meetings, with some 3,600 licensing opportunities posted.

More information at: http://www.ebdgroup.com/bioeurope/index.php

Media Contact

Dr. Evelyn Trummer-Gödl, VTU Technology GmbH
Tel: +43 (0) 316 4009 4000
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU offering powerful protein expression services and technology transfer at BIO Europe for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU brings broadest and most versatile protein expression platform to BIO International Convention 2014


VTU brings broadest and most versatile protein expression platform to BIO International Convention 2014


VTU Technology

Press Release | VTU Technology GmbH

MAY 08, 2014

Grambach, Austria: – Protein expression specialist VTU Technology will use June’s BIO 2014 International Convention at San Diego, California, to exhibit its world-leading Pichia pastoris recombinant platform that boasts the highest productivities ever recorded.

VTU will be able to provide detailed information on this next generation protein expression technology, along with other innovations and services, at its Booth 4407 in the Austrian Pavilion or through meetings arranged via the event’s Bio One-on-One partnering system.

“Our cutting-edge, exclusive, proprietary technologies and extensive know-how form the basis for the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production,” said Dr. Thomas Purkarthofer, VTU’s Head of Business Development.

Broad, versatile and powerful

“Together, these have enabled us to achieve the highest product titers ever reported for Pichia production processes confirming that VTU now possesses one of the most versatile and most powerful Pichia protein expression platforms in the world,” said Dr. Purkarthofer.

“We can guarantee tight development timelines and deliver production processes that are economically viable, robust, readily scalable and safe, obviating risk of viral or endotoxin contamination,” he added.

VTU are also hoping to use the conference to discuss technology transfers and out licensing opportunities for several products including Human Serum Albumin (HSA), Human Serum Transferrin, HSA-fusion proteins and cell culture proteins.

About VTU Technology

VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes yielding highest productivities (more than 20 g/L) of secreted protein for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries and in-house expression platform, complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About BIO International 2014

The BIO International Convention represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the USA, along with more than 30 other nations. The 2014 Convention will take place June 23-26 at the San Diego Convention Centre.

Hosted by the Biotechnology Industry Organization (BIO) this annual event is for members involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

First held in 1993, the BIO International Convention has attracted as many as 22,000 visitors and is now covered by some 400 journalists from around the world. The 2014 convention will feature an exhibition organized into more than 35 international pavilions as well as those representing the 21 US States with significant biotech industries.

Media Contact

Dr. Evelyn Trummer-Gödl, VTU Technology GmbH
Tel: +43 (0) 316 4009 4000
Email: e.trummer-goedl@vtu.com

Resources

Click on VTU brings powerful protein expression platform to BIO International for other information.
Click on VTU Technology to contact the company directly.


Supplier Information
Supplier: VTU Technology GmbH
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com


VTU to Present Groundbreaking Expression Technologies at Pichia 2014

Press Release – VTU Technology GmbH
VTU to Present Groundbreaking Expression Technologies at Pichia 2014

VTU Technology Logo

Contact Supplier: VTU Technology GmbH
Supplier Press Release: VTU to Present Groundbreaking Expression Technologies at Pichia 2014
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com

FEBRUARY 13, 2014

VTU to Present Groundbreaking Expression Technologies at Pichia 2014

Grambach, Austria: – VTU Technology, a world leader in Pichia pastoris protein expression, will be presenting groundbreaking extensions to the technology to the upcoming Pichia 2014 conference in California.

VTU is principal sponsor of the event. Its scientists will give three lectures at the conference that will provide insights into its latest research.

Methanol-free Breakthrough
On Day One, Dr. Iskandar Dib, Principal Scientist Process Development & Analytics, will talk about targeted process optimization at VTU and scale up to industrial scale. He will focus on VTU´s unique and groundbreaking methanol-free promoter variants, a novel technology that enables strong expression clearly outperforming conventional promoter systems. Besides abolishing toxic and explosive methanol as a substrate while retaining high expression levels of up to 15 g/L (e.g. for a cellulose hydrolyzing enzyme), the new technology also reduces oxygen consumption and therefore needs significantly less cooling effort in bioreactor cultivation. Dr. Dib will demonstrate that targeted process optimization can deliver five-fold increases in process performance in the production of a recombinant hydrolase.

Unique Recombinant Platform
On Tuesday, March 4, Dr. Roland Weis, Head of Operations, will present VTU achievements in high-level production and characterization of uniform GlcNAc2Man5-decorated proteins by Pichia pastoris, showing how the company is expanding its service offerings by adding RCT´s revolutionary Pichia GlycoSwitch® system for homogeneous N-glycosylation to its portfolio. This unique combination of technologies acts synergistically to offer a new dimension of recombinant protein expression and create a high performance production platform for recombinant glycoproteins with outstanding product yields and controlled GlcNAc2Man5-pattern or generation of other human-like glycoforms.

HSA-fusion Architecture
Later the same day, Dr. Aid Atlic, Research Scientist Development & Fermentation, will talk about the implications on producibility and in vitro as well as in vivo characteristics of several fusion proteins comprising a chemokine fused to HSA.

Fusion of payloads to HSA takes advantage of the inherent high secretion rate of HSA while simultaneously from increased half-life in vivo. Dr. Atlic will show how various HSA-fusion architectures of ProtAffin´s monocyte chemotactic protein-1 PA910 were designed and the respective proteins produced using VTU Technology´s advanced Pichia pastoris expression platform.

Powerful Platform
Dr. Thomas Purkarthofer, VTU’s Head of Business Development, commented: “This is our third appearance at the Pichia congress and we are proud to be platinum sponsor of this event that celebrates the breathtaking advances which have been achieved in yeast protein expression.”

“In their three presentations, my colleagues will demonstrate that the technology is still evolving very fast and that VTU now possesses one of the most versatile and most powerful Pichia protein expression platforms in the world,” said Dr. Purkarthofer.

“To date, VTU has established a broad range of technologies and know-how for the fast-track generation of high performance Pichia protein production strains and processes. Exclusive proprietary technologies and the profound experience of our VTU team have led to ultra-competitive production processes for a wide range of recombinant proteins,” he added.

About VTU Technology
VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 20 g/L of secreted protein for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries & in-house expression platform, complemented by its optimized gene design &cloning strategies as well as high-throughput screening & cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.

About Pichia 2014
The Pichia 2014 Conference, to be held March 2-5 at the Catamaran Hotel and Spa in San Diego, California, has been organised by Research Corporation Technologies (RCT) and bioGrammatics to celebrate 30 years of Pichia research and development. During that time, the technology has led to more than 70 commercial products, two approved therapeutics and more than 5000 proteins expressed.

The conference will explore how this extraordinary system has progressed over the last three decades, producing an ever-expanding variety of novel proteins.

Contact:
VTU Technology GmbH
Dr. Evelyn Trummer-Gödl
Head of Business Development
Tel: +43 (0) 316 4009 4000
Email: e.trummer-goedl@vtu.com

For more information about VTU to present groundbreaking expression Technologies at Pichia 2014, please contact VTU Technology directly.

VTU Technology to Showcase Next Generation Protein Expression Platform

Press Release – VTU Technology GmbH
VTU Technology to Showcase Next Generation Protein Expression Platform

VTU Technology Logo

Contact Supplier: VTU Technology GmbH
Supplier Press Release: VTU Technology to Showcase Next Generation Protein Expression Platform
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com

OCTOBER 01, 2013

VTU Technology to Showcase Next Generation Protein Expression Platform

Austrian laboratory VTU Technology, the leader in Pichia pastoris protein expression services, is to use two European networking and partnering events to showcase its revolutionary Pichia pastoris protein expression platform.

VTU will be present at CPhI Worldwide 2013, on 22-24 October at Messe Frankfurt. This leading international pharmaceutical networking event brings together over 30,000 attendees from 140 countries, along with 2,200 exhibitors. VTU will be using the CPhI Global Meetings programme to identify potential prospects interested in Pichia pastoris’ revolutionary multi-expression capabilities as well as using the portal to arrange meetings with visitors who would like to meet VTU Technology at the event.

The company will also attend BIO-Europe, Europe´s largest partnering conference, held in Vienna, November 4-6. The 2013 event is likely to attract almost 3,000 delegates from more than 50 countries.

VTU Technology will be using EBD Group’s partneringONE® networking system to pre-arrange private one-to-one meetings and will be presenting its outstanding Pichia pastoris protein expression platform & services and latest technology developments at the Austrian Country Seminar on Monday, November 4 , 4 – 5 p.m.

NextGen Protein Expression
Hailed as the ‘next generation’ of protein expression, Pichia pastoris is a proprietary platform that combine exclusive technologies with FTO tools and highly elaborated procedures to provide its customers high-performance production protein strains and associated economically viable and scalable protein production processes.

VTU´s highly approved 1st generation promoter variants – forms the core of VTU´s cutting-edge in-house Pichia pastoris toolbox enabling high-level protein expression (up to 20 g/L of secreted protein). This unmatched technology platform is complemented by novel 2nd generation AOX1 promoter variants allowing for methanol-free expression thus providing customers with high-performance expression strains that are non-dependent on methanol induction. VTU´s exclusive promoter libraries provide an unprecedented genetic diversity with superior regulatory properties for fine-tuning of gene expression by selecting the perfect match of promoter and target combinations.

Researchers at VTU have consistently demonstrated the platform’s ability to rapidly produce a wide range of different proteins, including serum proteins, cytokines, Fabs and other antibody derived fragments, scaffold proteins, fusion proteins and enzymes.

As of autumn 2013 VTU Technology will be able to expand its service offerings by adding RCT´s revolutionary Pichia GlycoSwitch® system (e.g. for homogeneous Man5 antibodies) to its portfolio alongside VTU´s exclusive, established Pichia pastoris expression platform. This unique combination of technologies acting synergistically offers a new dimension of recombinant protein expression and creates a high performance production platform for recombinant glycoproteins with outstanding product yields and controlled Man5 or generation of other human-like glycoforms.

In addition, VTU Technology offers outlicensing/co-development opportunities for several recombinant proteins such as recombinant human serum albumin (rHSA), recombinant human serum transferrin (rHST), HSA- fusion proteins and cell culture proteins.

VTU recently signed a licensing agreement with Minapharm that provided access to Pichia pastoris technology for development of a therapeutic rHSA.

Networking
VTU will use the advanced networking facilities at BIO-Europe and at CPhI Worldwide to explore further potential collaborations to harness the new Pichia pastoris technology.

Dr. Thomas Purkarthofer, VTU’s Head of Business Development, said the company has been a consistent attendee of BIO-Europe, having been present at every event since 2008.

“At BIO-Europe and now also at CPhI Worldwide, we will be available to provide more information on our Pichia pastoris protein expression platform, including related services and latest technology developments,” he added.

“We hope to give every company interested in VTU and our technologies the possibility to set up face-to-face meeting to discuss potential upcoming projects or collaborations,” said Dr. Purkarthofer.

VTU is inviting visitors to contact the company directly or via the event partnering systems, to arrange exploratory meetings. The CPhI global meetings programme and the BIO-Europe networking system are already open.

About VTU Technology
VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 20 g/L of secreted protein for a wide range of biologics and other proteins.

VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its optimized gene design and cloning strategies, exclusive AOX1 promoter libraries & in-house expression platform and high-throughput screening & cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma & life science, chemistry, as well as power and fuel industry.

Contact:
VTU Technology
Thomas Purkarthofer
Head of Business Development
Tel: +43 (0) 316 4009 4017
Email: thomas.purkarthofer@vtu.com

For more information about VTU´s Pichia pastoris protein expression platform & services, please contact VTU Technology directly.

Therapeutic, Recombinant Human Serum Albumin (rHSA) VTU Technology Signs Agreement with Minapharm Pharmaceuticals

Press Release – VTU Technology GmbH
Therapeutic, Recombinant Human Serum Albumin (rHSA) – VTU Technology Signs Agreement with Minapharm Pharmaceuticals

VTU Technology Logo

Contact Supplier: VTU Technology GmbH
Supplier Press Release: Therapeutic, Recombinant Human Serum Albumin (rHSA)
Address: A-8074 Grambach, Parkring 18, Austria
Tel: +43 (316) 4009 4000
Fax: +43 (316) 4009 4010
Website: www.vtu-technology.com

NOVEMBER 27, 2012

Therapeutic, Recombinant Human Serum Albumin (rHSA) – VTU Technology Signs Agreement with Minapharm Pharmaceuticals

VTU Technology and Minapharm Pharmaceuticals have today announced they have signed a licensing agreement which will see them partner to develop a therapeutic, recombinant Human Serum Albumin (rHSA).

In accordance with the agreement, Minapharm will gain access to VTU´s Pichia pastoris protein expression technology for rHSA production. Both parties have clear roles in the collaborative development project, VTU will apply its proven process for expression strain development and bioprocess optimization for biopharmaceuticals production. Minapharm, via its subsidiary, Rhein-Minapharm-Biogenetics, will carry out the pertinent process research & development, production and commercialization of the target therapeutic protein.

The agreement allows Minapharm exclusivity to market the product in Egypt with options for other Middle Eastern countries. VTU will take control of promotional rights in Rest of the World. Revenue from the product will be shared by both companies. Further financial details were not disclosed.

“We are delighted to collaborate with Minapharm in this important project. This agreement underlines the attractiveness of our Pichia pastoris protein expression platform and demonstrates VTU´s capabilities to leverage the high potential of our technology”, said Dr. Thomas Purkarthofer, Head of Business Development of VTU Technology.

Frank Mueller, Senior Manager Biopharmaceutical Project Minapharm added, “We very much look forward to a long and successful relationship with VTU. This event further substantiates Minapharm’s position at the regional forefront of research, development and marketing of innovative recombinant DNA products. This collaboration agreement with VTU offers a viable opportunity for Minapharm to further sustain its regional market leadership while fostering new models of cost-effective biotherapeutic innovation.”

About VTU Technology
VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 20 g/L of secreted protein for a wide range of biologics and other proteins (e.g. serum proteins, cytokines, Fabs and antibody derived fragments, (HSA&Fc) fusion proteins, scaffolds, vaccines, enzymes). VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its optimized gene design and cloning strategies, exclusive AOX1 promoter libraries & in-house expression platform and high-throughput screening & cultivation regime, combined with excellent know-how in fermentation and downstream process development.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industry. www.vtu-technology.com

About Minapharm
Minapharm Pharmaceuticals, headquartered in Cairo with its production facilities in the tenth of Ramadan, is among the leading prescription medicine companies in Egypt and the Middle East. The company is specialized in the manufacture and marketing of innovative pharmaceuticals and through its subsidiary Rhein-Minapharm-Biogenetics, in the research, development and manufacturing of biopharmaceuticals. Its biotech subsidiary is focussing on the core therapeutic areas of liver disease and thrombosis & haemostasis.

With five therapeutic proteins already marketed and several in the pipeline, Minapharm’s competence lies in decreasing time to market without compromising ethical and safety standards.

By combining its expertise in pharmaceuticals and leadership in biopharmaceuticals Minapharm, along with its worldwide strategic alliances, contributes significantly to the quality of life of many people in the region. Minapharm employs a collective workforce of over 750 and is listed on the Cairo and Alexandria stock exchange (Symbol: MIPH). For more information on Minapharm and its products please visit www.minapharm.com and www.rhein-minapharm.com

Contact:
VTU Technology
Thomas Purkarthofer
Head of Business Development
Tel: +43 (0) 316 4009 4017
Email: thomas.purkarthofer@vtu.com

Minapharm Pharmaceuticals
Frank Mueller
Senior Manager Biopharmaceutical Projects
Email: mueller@minapharm.com

For more information or to discuss therapeutic, recombinant Human Serum Albumin (rHSA) please contact us directly.